

Communication

Ugi Reaction on α -Phosphorated Ketimines for the Synthesis of Tetrasubstituted α -Aminophosphonates and Their Applications as Antiproliferative Agents

Adrián López-Francés, Xabier del Corte, Edorta Martínez de Marigorta, Francisco Palacios * and Javier Vicario *

Departamento de Química Orgánica I, Centro de Investigación y Estudios Avanzados "Lucio Lascaray", Facultad de Farmacia, University of the Basque Country, UPV/EHU Paseo de la Universidad 7, 01006 Vitoria-Gasteiz, Spain; adrian.lopez@ehu.eus (A.L.-F.); xabier.delcorte@ehu.es (X.d.C.); edorta.martinezdemarigorta@ehu.eus (E.M.d.M.)

Correspondence: francisco.palacios@ehu.eus (F.P.); javier.vicario@ehu.eus (J.V.); Tel.: +34 945013103 (F.P.); +34 945013087 (J.V.)

Abstract: An Ugi three-component reaction using preformed α -phosphorated *N*-tosyl ketimines with different isocyanides in the presence of a carboxylic acid affords tetrasubstituted α -aminophosphonates. Due to the high steric hindrance, the expected acylated amines undergo a spontaneous elimination of the acyl group. The reaction is applicable to α -aryl ketimines bearing a number of substituents and several isocyanides. In addition, the densely substituted α -aminophosphonate substrates showed in vitro cytotoxicity, inhibiting the growth of carcinoma human tumor cell line A549 (carcinomic human alveolar basal epithelial cell).

Keywords: multicomponent synthesis; Ugi reaction; α -aminophosphonates; tetrasubstituted carbons; antiproliferative effect

1. Introduction

In the interdisciplinary research field of chemical biology and drug discovery, diversity-oriented synthesis is an interesting model for the production of large chemical libraries of small molecules, bearing multiple functional groups, in order to explore their influence into the biological properties of those substrates [1–3]. At the heart of this concept, multicomponent reactions (MCRs) have become a mainstay of medicinal and organic chemistry that allow the preparation of a broad spectrum of compounds with a reduced number of synthetic steps [4,5]. In such synthetic procedures, three reactants or more are combined in the same pot to generate a new substrate, whose structure shows portions of all the starting materials. The atom economy, efficiency, mild conditions and high convergence of MCRs justify a central place in the toolbox of diversity-oriented synthesis [6,7]. Among the numerous MCRs described along the last decades, the Ugi reaction [8] has been verified as one of the most important multicomponent processes for the synthesis of peptide-like structures [9,10]. The Ugi reaction consists on a nucleophilic attack of an isonitrile 6 to an iminium ion 5, a salt composed of a carboxylic acid 4 and an imine 3, which is often generated in situ from a carbonyl derivative 1 and an amine 2. Then, a second nucleophilic attack of the carboxylate anion in the intermediate nitrilium species 7 results in the formation of acyl imidate 8. The reaction ends with an irreversible Mumm rearrangement of species 8, leading to α -amido amide substrates 9 in a very efficient manner (Scheme 1). Remarkably, the whole reaction is driven by the Mumm rearrangement since all other species involved in the mechanism are in equilibrium. Due to its versatility, the Ugi reaction has become increasingly practical in the synthesis of many active complex drugs and natural products [11-13].

Citation: López-Francés, A.; del Corte, X.; de Marigorta, E.; Palacios, F.; Vicario, J. Ugi Reaction on α-Phosphorated Ketimines for the Synthesis of Tetrasubstituted α-Aminophosphonates and Their Applications as Antiproliferative Agents. *Molecules* **2021**, *26*, 1654. https://doi.org/10.3390/ molecules26061654

Academic Editor: Ana Maria Gomez Neo and Carlos Fernández Marcos

Received: 25 February 2021 Accepted: 14 March 2021 Published: 16 March 2021

Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).





Scheme 1. The accepted mechanism for an Ugi reaction.

On the other hand, the α -aminophosphonic acid framework enjoys significant attention in medicinal sciences, due to its unique ability to mimic the transition state of peptide cleavage in an irreversible fashion, thus blocking very efficiently enzymes implicated in proteolysis processes (Figure 1). For this reason, α -aminophosphonic acid derivatives and their phosphapeptides display an assorted biological activity, including anticancer properties [14–18]. α -Aminophosphonic acids can be considered as structural isosters of α aminoacids, where the flat carboxylic acid group has been replaced by a phosphonic acid group, and one of the most straightforward methods for the preparation of both compounds, α -aminoacids and α -aminophosphonic acids, consists on the addition of carbon nucleophiles to α -iminoesters or α -iminophosphonates, respectively [19,20]. While an Ugi reaction using α -iminoesters to afford α , α -diamino acid derivatives is documented [21,22] no examples are described using α -iminophosphonates as starting materials. In addition, the use of ketones or ketimines as substrates in such reactions, in order to generate structures bearing tetrasubstituted carbons, entails additional obstacles, since the inherent steric factors observed in these systems enhance the difficulty level in these synthetic methodologies [23]. In addition, the use of acyclic ketones typically requires preformation of the imine intermediate in a separate step, and the yields of the Ugi are often modest [24– 261



Figure 1. Phosphonopeptides mimic the transition state for peptide cleavage.

In this context, during the course of our research on the addition of nucleophiles to α -ketiminophosphonates, in the past, we achieved the synthesis of tetrasubtituted α -aminophosphonates [27] using cyanide [28], organometallics [29] and nitromethane [30] as nucleophiles and, more recently, we have reported the first enantioselective Reformatsky reaction using acyclic ketimines as substrates [31]. Continuing with our interest in the chemistry of organophosphorus compounds, we thought that α -ketiminophosphonates would be excellent substrates in Ugi reactions for the generation of phosphorated peptide-like structures bearing tetrasubstituted carbons. Due to the great occurrence of tetrasubstituted carbons in natural products and drugs [32], the high affinity of α -aminophosphonates to proteolytic enzymes and the synthetic versatility of multicomponent reactions, a synthetic protocol of an Ugi reaction using α -phosphorated ketimines would be of great value in organic and medicinal chemistry.

2. Results and Discussion

2.1. Chemistry

N-tosyl α -ketiminophosphonates **10** can be synthesized by a formal oxidation of trisubstituted aminophosphonates as reported in literature [28,31]. In our first experiment we studied the Ugi reaction of *N*-tosyl ketimine **10a** (R¹ = Me, R² = Ph) with phenyl acetic acid **11** and cyclohexyl isocyanide **12a** (R³ = Cy) under the typical reaction conditions (Scheme 2). After stirring a mixture of the three compounds in CH₂Cl₂ at room temperature for 1 h, NMR showed the complete disappearance of the starting materials and formation of tetrasubstituted α -aminophosphonate **13a**. Due to the insolubility of the starting materials, the use of other environmentally friendly solvents led to the formation of substrate **13a** in lower yields and longer reaction times.



Scheme 2. Scope for the Ugi reaction of α -ketiminophosphonates 10.

With this result in hand, next we extended the Ugi protocol to different α -iminophosphonates **10** and isocyanides **12** using phenylacetic acid **11** in CH₂Cl₂ (Scheme 2). First, different isocyanides **12** were tested in the reaction using ketimine **10a** (R¹ = Me, R² = Ph) derived from dimethylphosphonate. The reactions proceed fast (1 h) and with good yields, not only using cyclohexyl isocyanide **12a** (R³ = Cy), but also with methyl isocyano-acetate **12b** (R¹ = CH₂CO₂Me) or benzyl isocyanide **12c** (R³ = Bn) to afford α -aminophosphonates **13b–c** (Scheme 2).

Next, diethyl, dibenzyl and di-*iso*-propyl phosphonate substituted ketimines **10b–d** ($R^1 = Et$, Bn, *i*Pr,) were tested as electrophilic substrates with very good results but different reactivity. In the case of diethylphosphonates **13d–f** ($R^1 = Et$, $R^2 = Ph$), and dibenzylphosphonates **13g** ($R^1 = Bn$, $R^2 = Ph$) the reactions proceed to full conversion after 6 h and even longer reaction times of 14 h are needed for di-*iso*-propylphosphonates **13h–j** (R^1

= iPr, R² = Ph) (Scheme 2). These differences in the reactivity related to the size of the phosphonate substituents are in agreement with what has been observed in similar reactions [28,30].

Then, the scope of the reaction was extended to the use of phosphorated ketimines bearing substituted aromatic rings. Aromatic ketimines holding strong electron withdrawing substituents such as a *para*-nitro group showed very good reactivity and aminophosphonate **13k** was obtained in very good yield after 1 h at room temperature (Scheme 2). The reaction is also fast using ketimines with halogenated aromatic groups. Several halogen substituted aromatic ketimines were successfully used in the reaction, including *para*-substituted aromatic rings containing bromine or chlorine to yield halogenated α aminophosphonates in full conversion after 1 h (Scheme 2, **131–m**). The reaction tolerates also the presence of an *ortho*-fluor substituted aromatic ring in (Scheme 2, **13n**) and even the existence of a perfluorinated phenyl group (Scheme 2, **13o**). Besides, when aromatic ketimines substituted by electron donating groups were used as substrates, an increase in the reaction times was observed. However, α -aminophosphonates **13p–q** were obtained in full conversion after 14 h (Scheme 2).

Tetrasubstituted α -aminophosphonates **13** were characterized on the basis of their ¹H, ³¹P, ¹⁹F and ¹³C NMR, IR spectra and high-resolution mass spectra (see Supplementary Materials for the detail). For example, ¹H NMR spectrum α -aminophosphonate **13a** presents the signals corresponding to the aliphatic cyclohexyl moiety with several chemical shifts in the interval $\delta_{H} = 0.92 - 1.91$ ppm for the five methylene groups and an additional multiplet at $\delta_{\rm H}$ = 3.77 ppm for the CH bonded to the nitrogen. The phosphonate moiety is seen as two representative doublets at δ_H = 3.80 ppm (³J_{PH} = 10.5 Hz) and δ_H = 3.99 ppm $(^{3}J_{PH} = 10.7 \text{ Hz})$, typical for the diastereotopic methoxy groups at the phosphonate. The presence of the tosyl group is evident from the chemical shift for its *para*-methyl substituent at $\delta H = 2.33$ ppm, that appears as a singlet, and the two doublets at $\delta H = 7.00$ and 7.16 ppm (³JHH = 8.3 Hz), corresponding to the four aromatic protons, that appear partially overlapped with the five protons of the phenyl substituent in the interval at $\delta_{H} = 6.99-7.25$ ppm. The sulfamide and amide NH protons appear as two doublets that interchange with D₂O at δ H = 6.47 ppm (³JPH = 8.2 Hz) and δ H = 6.76 ppm (³JHH = 6.4 Hz), respectively. Due to the low interchange rate in such acidic protons, the signal corresponding to the NH of the sulfamide moiety is coupled with the magnetically active phosphorus atom, while the amide NH is coupled with the neighboring CH of the cyclohexyl group.

In addition, in the ¹³C NMR spectrum of α -aminophosphonate **13a**, the cyclohexyl group can be detected by the chemical shift at $\delta c = 49.8$ ppm, corresponding to its methyne group, bonded to the nitrogen atom and, due to the stereogenic center present in the structure, the other five methylene carbons show five different signals at δ_{C} = 24.5, 24.6, 25.4, 32.1 and 32.3 ppm. Here, again, the two diastereotopic methoxy groups at the phosphonate moiety are seen as two doublets at δ_{H} = 55.8 ppm (²J_{PC} = 8.2 Hz) and δ_{C} = 55.2 ppm $(^{2}J_{PC} = 7.5 \text{ Hz})$. The most characteristic chemical shift of α -aminophosphonate **13a** in ^{13}C NMR is certainly the doublet corresponding to the quaternary carbon directly bonded to the phosphonate that appears at $\delta c = 68.5$ ppm and presents a strong coupling with the phosphorus atom (1 JPC = 157.2 Hz). The presence of the tosyl group is here deduced from the chemical shift corresponding to its *para*-methyl substituent at $\delta c = 21.6$ ppm and the aromatic carbons with two signals at $\delta c = 126.5$ and 129.1 ppm for each of the two couples of the equivalent CH carbons of the aromatic ring, as well as another two signals for the two quaternary carbons at δ_{C} = 142.4 and 139.2 ppm, the latter seen as a doublet due to the coupling with the phosphorus atom ($^{4}J_{PC} = 1.6 \text{ Hz}$). In the aromatic region it also appears the chemical shifts of the carbons corresponding to the phenyl ring, with the signals corresponding to the two pairs of equivalent CH carbons at δ_c = 127.9 and 130.2 ppm, the second as a doublet coupled with the phosphorus atom (3 JPC = 8.3 Hz). The fifth aromatic CH appears at $\delta_{\rm C}$ = 128.7 ppm and the quaternary carbon as a doublet at $\delta_{\rm C}$ = 131.9 (²J_{PC} = 1.8 Hz). Surprisingly, the amide carbonyl group does not show coupling with the phosphorus atom and the signal appears as a singlet at $\delta c = 166.1$ ppm.

The most relevant absorptions observed in IR spectrum correspond to the amide, sulfamide and phosphonate moieties. The stretching vibration of amide and sulfamide NH groups can be observed at v = 3426 and 3333 cm^{-1} , respectively. In addition, two strong bands are observed at v = 1678 and 1256 cm^{-1} , correspond to the vibration of amide C=O and phosphonate P=O bonds. Finally, the spectrum shows two characteristic absorptions v = 1333 and 1164 cm^{-1} that correspond to the asymmetric and symmetric stretching vibration of the sulfonyl group.

Regarding the mechanism of the reaction, we theorized that compounds **13** might be formed by a typical three-component Ugi reaction that leads to the formation of the predicted phosphorated α -amido amide **15**, followed by a spontaneous cleavage of the acyl group, due to the high steric hindrance present in the intermediate **15** (Scheme 3). In fact, the same behavior has been observed in the acylcyanation reaction of *N*-tosyl ketimines **10** (R² = Ar, PG = Ts) with pyruvonitrile [28]. In our attempts to detect the acylated intermediate **15**, different carboxylic acids were used in the reaction, but α -aminophosphonate **13a** was obtained in all cases, even when acetic, trifluoroacetic or benzoic acid were used as reagents. Nevertheless, the reaction does not proceed in the absence of a carboxylic acid, which at least indicates that the formation of iminium species is crucial prior to the nucleophilic attack of isocyanide.



Scheme 3. Ugi reaction of N-tosyl ketimines 10 and 14, phenyl acetic acid 11 and isocyanides 12.

In order to check if the Mumm rearrangement was indeed taking place, next we used *N*-trityl aldimine **14** ($\mathbb{R}^2 = \mathbb{H}$, $\mathbb{PG} = \mathbb{CPh}_3$) [33] as the electrophile substrate, in the presence of phenylacetic acid **11** and cyclohexyl isocyanide **12a** ($\mathbb{R}^3 = \mathbb{Cy}$) (Scheme 3). Due to the utilization of an aldimine derived electrophile in the reaction, a less hindered structure is expected in the Ugi adduct, which may result in the isolation of species **15**. However, in this case, trisubstituted α -aminophosphonate **16** was obtained in full conversion, where, the formation of α -amido amide **15** is followed by a spontaneous cleavage of the bulky trityl protecting group (Scheme 3).

Although this last experiment supports an Ugi three-component mechanism of the process, still we were skeptical about the real role of the carboxylic acid in the system. It is true that, considering the accepted mechanism for the Ugi reaction, only through the irreversible Mumm rearrangement all the equilibrium in the process can be displaced to the final products. But yet, it might be vaguely possible that, in the case of our ketimines **10**, a simple addition of isocyanide to iminium species could afford tetrasubstituted α -aminophosphonate **13a** after an irreversible hydrolysis of the nitrilium intermediate, due to the presence of traces of water in the solvent. Then the key question to be addressed is: is the third reactant of the multicomponent reaction a carboxylic acid or is it just water?

This matter could be resolved in view of the fact that the isolation of intermediate **15** was achieved when *para*-fluorophenyl or *para*-trifluoromethylphenyl substituted α -phos-

phorated ketimines **101,m** (R = CF₃, F) were used as the electrophile unit in the Ugi reaction. Using phenylacetic acid **11** and cyclohexyl isocyanide **12a**, phosphorated α -amido amides **15a**,**b** were obtained, without the elimination of the amide group (Scheme 4). Although substrate **15b** proved to be very stable, trifluoromethyl substituted α -amido amide **15a** underwent spontaneous hydrolysis of the amide under the air moisture to yield tetrasubstituted α -aminophosphonate **13r**.



Scheme 4. Ugi reaction of ketimines 101,m.

NMR properties of phosphorated α -amido amides **15** were very similar to the parent substrates **13** except for some significant differences. In the case of substrate **15b**, the presence of benzylamide group was evident in ¹³C NMR by the existence of the chemical shifts for two carbonyl groups at $\delta_{\rm C}$ = 176.4 and 165.3 ppm and a methylene carbon at $\delta_{\rm C}$ = 45.7 ppm (DEPT). Key features for this compound in ¹H NMR spectrum are mainly the two diastereotopic protons of the benzyl group that appear as doublets at $\delta_{\rm C}$ = 3.92 and 4.16 ppm with a strong geminal coupling constant ²*J*_{HH} = 17.1 Hz. It is also noteworthy the presence of an atypical doublet for two equivalent aromatic protons at $\delta_{\rm C}$ = 8.26 ppm (³*J*_{HH} = 7.9 Hz) that corresponds either to the benzyl or the tosyl moiety that appears especially deshielded, which is probably originated by the proximity of both aromatic rings due to the steric crowding present in the structure.

In order to shed more light on this issue, we set up an additional experiment where the three-component reaction was performed using of *N*-tosyl ketimine **10a**, thioacetic acid **17** and cyclohexyl isocyanide **12a** in CDCl₃. However, after 1h at room temperature a complex mixture was observed in the reaction vessel. We hypothesized that the high steric hindrance due to the presence of the tetrasubstituted carbon together with the higher Van der Waals radius of the sulfur atom versus the oxygen (180 pm vs. 152 pm) could be the reason of such different behavior.

For this reason, next we tried the Ugi reaction using a less sterically demanding isocyanide such as methyl isocyanoacetate **12b** (Scheme 5). In this case, formation of thioamide **18** was observed in full conversion. The presence of a sulfur atom in the structure confirms unambiguously the Ugi mechanism of our reaction through the formation of iminium species **19** from α -ketiminophosphonate **10a** and thioacid **17**, followed by a nucleophilic attack of isocyanide **12b**. Then, a second nucleophilic attack of thiocarboxylate anion in the intermediate nitrilium species **20** results in the formation of acyl thioimidate **21**. To complete the Ugi sequence, the acyl transfer from thioimidate **21** to the adjacent nitrogen atom yields irreversibly phosphorated α -amido amide **22** that, due to the high steric hindrance owing to the presence of the tetrasubstituted carbon, undergoes a spontaneous cleavage of the acyl group that affords finally tetrasubstituted α -aminophosphonate **18**.



Scheme 5. Ugi reaction of N-tosyl ketimine 10a, thioacetic acid 17 and methyl isocyanoacetate 12b.

Nevertheless, attempts to isolate compound **18** failed due to its decomposition during the workup, but the identity of thioamide **22** was confirmed by NMR of the crude reaction. ³¹P NMR showed the disappearance of the starting imine ($\delta_P = 6.6$ ppm) and the formation of a major compound with a chemical shift at $\delta_P = 18.7$ ppm. On the other hand, ¹H NMR showed two clear doublets at $\delta_H = 3.90$ ppm (³*J*_{PH} = 10.7 Hz) and $\delta_H = 3.79$ ppm (³*J*_{PH} = 10.8 Hz), typical for the diastereotopic methoxy groups at the phosphonate, that suggest the formation of a stereogenic carbon close to the phosphorus atom and a broad triplet that interchanges with D₂O, at $\delta_H = 8.63$ ppm (¹*J*_{NH} = 4.0 Hz), that may correspond to the NH of thioamide group, where the proton is coupled with the quadrupolar nucleus of ¹⁴N. More importantly, ¹³C NMR shows a doublet for the quaternary C-P (DEPT) at δ_C = 58.6 ppm (¹*J*_{PH} = 167.2 Hz), and the characteristic chemical shift for the C=S group of thioamides at $\delta_C = 199.2$ ppm. A similar result was obtained using thiobenzoic acid instead of thioacetic acid.

Additionally, the hydrolysis the phosphonate group to its phosphonic acid derivative **23** can be performed under mild conditions in chloroform by the treatment of **13b** with trimethylsilyl bromide at room temperature. The subsequent aqueous workup yields α -aminophosphonic acid **23** in almost quantitative yield (Scheme 6).



Scheme 6. Hydrolysis of phosphonate ester 13b.

2.2. Biological Results

In vitro cytotoxicity of tetrasubstituted α -aminophosphonate derivatives **13**, **15** and **23** was evaluated by testing their antiproliferative activities against A549 cell line (carcinomic human alveolar basal epithelial cell). Cell counting kit (CCK-8) assay was used for the evaluation of growth inhibition. Moreover, nonmalignant MRC5 lung fibroblasts were tested for studying selective toxicity [34] and chemotherapeutic doxorubicin is used as reference value. The cell proliferation inhibitory activity is shown as IC₅₀ values (Table 1).

Entry	Cmpd.	IC50 (μM)		Enter	Cmmd	IC50 (μM)	
		A549	MRC5	Entry	Cmpa.	A549	MRC5
1	13a	>50	n.d.	6	13n	>50	n.d.
2	13d	>50	n.d.	7	13p	14.56 ± 2.53	>50
3	13g	16.136 ± 1.14	>50	8	13r	>50	>50
4	13h	19.72 ± 3.70	>50	9	15a	28.76 ± 3.20	>50
5	13k	>50	n.d.	10	23	>50	n.d.

Table 1. Antiproliferative activity of α -aminophosphonate derivatives **13**, **15** and **23**.

In a preliminary study, we tested the cytotoxicity of simple phenyl substituted α -aminophosphonates **13a–j** as lead compounds. Although no grown inhibition activity was observed for dimethyl and diethylphosphonates **13a,f** (Table 1, Entries 1–2), diben-zylphosphonate **13g** showed some cytotoxicity against A549 cell line with an IC₅₀ value of 16.46 ± 1.49 μ M and, interestingly, very good selectivity was also obtained towards MRC5 nonmalignant cell line (Table 1, Entry 3). Besides, bulkier di*-iso*-propylphosphonate **13h**, derived from cyclohexyl isocyanide, presented an IC₅₀ value of 19.72 ± 3.70 μ M (Table 1, Entry 4).

Then we studied the introduction of substituents at the aromatic ring of tetrasubstituted aminophosphonates **13**. Scarce cytotoxic effect was found for *para*-nitrophenyl substituted substrate **13k**, bearing an electron poor aromatic group (Table 1, Entry 5). Although the effect of the introduction of fluorine atoms in the structure of organic compounds is rather difficult to predict, very often it leads to increased activities [35–37]. For this reason, next we tested the in vitro cytotoxicity of fluorine containing α -aminophosphonates **13n**. However, *ortho*-fluorophenyl and *para*-trifluoromethylphenyl substituted substrates **13n**, **r** presented IC₅₀ values higher than 50 µM (Table 1, Entries 6, 8). Interestingly, thioether derived α -aminophosphonate **13p**, showed a considerable antiproliferative activity with an IC₅₀ value of 14.56 ± 2.53 µM and a very good selectivity towards MRC5 cell line (Table 1, Entry 7). Phosphorated α -amido amide **15a** bearing a *para*-trifluomethylphenyl substituent showed better toxicity than its parent compound **13r** with an IC₅₀ value of 28.76 ± 3.20 µM and a good selectivity towards nonmalignant cells (Table 1, Entry 8 vs. Entry 9). Finally phosphonic acid derivative **23** did not provide any toxicity against A549 cell line (Table 1, Entry 10).

3. Materials and Methods

3.1. Chemistry

3.1.1. General Experimental Information

Solvents for extraction and chromatography were technical grade. All solvents used in reactions were freshly distilled from appropriate drying agents before use. All other reagents were recrystallized or distilled as necessary. All reactions were performed under an atmosphere of dry nitrogen. Analytical TLC was performed with silica gel 60 F254 plates. Visualization was accomplished by UV light. ¹H, ¹³C, ³¹P and ¹⁹F-NMR spectra were recorded on a Varian Unity Plus (Varian Inc, NMR Systems, Palo Alto, CA, USA) (at 300 MHz, 75 MHz, 120 MHz and 282 MHz respectively) and on a Bruker Avance 400 (Bruker BioSpin GmbH, Rheinstetten, Germany) (at 400 MHz for ¹H, and 100 MHz for ¹³C). Chemical shifts (δ) are reported in ppm relative to residual CHCl₃ (δ = 7.26 ppm for ¹H and δ = 77.16 ppm for ¹³C NMR) and using phosphoric acid (50%) as external reference ($\delta = 0.0$ ppm) for ³¹P NMR spectra. Coupling constants (*J*) are reported in Hertz. Data for ¹H NMR spectra are reported as follows: chemical shift, multiplicity, coupling constant, integration. Multiplicity abbreviations are as follows: s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet). ¹³C NMR peak assignments were supported by distortionless enhanced polarization transfer (DEPT). High resolution mass spectra (HRMS) were obtained by positive-ion electrospray ionization (ESI). Data are reported in the form m/z (intensity relative to base = 100). Infrared spectra (IR) were taken in a Nicolet iS10 Thermo Scientific spectrometer (Thermo Scientific Inc., Waltham, Massachusetts, MA, USA) as neat solids. Peaks are reported in cm⁻¹.

3.1.2. Compounds Purity Analysis

All synthesized compounds were analyzed by HPLC to determine their purity. The analyses were performed on Agilent 1260 infinity HPLC system (Agilent, Santa Clara, CA, USA) using a CHIRALPAK® IA column (5 μ m, 0.54 cm ø × 25 cm, Daicel Chiral Technologies, Illkirch Cedex, France) at room temperature. All the tested compounds were dissolved in dichloromethane, and 5 μ L of the sample was loaded onto the column. Ethanol and heptane were used as the mobile phase, and the flow rate was set at 1.0 mL/min. The maximal absorbance at the range of 190–400 nm was used as the detection wavelength. The purity of all the tested α -aminophosphonate derivatives **13**, **15** and α -aminophosphonaic acid **23** is >95%, which meets the purity requirement by the Journal.

3.1.3. Experimental Procedures and Characterization Data for Compounds 13, 15, 16 and 23

General Procedure for the Synthesis N-Tosyl α -Iminophosphonates 10

Following a literature procedure, [28,31] to a solution of the corresponding tetrasubstituted *N*-tosyl α -aminophosphonate (10 mmol) in CH₂Cl₂ (30 mL) was added trichloroisocyanuric acid (6.97 g, 30 mmol). The resulting suspension was stirred at 0 °C until disappearance of the starting *N*-tosyl α -aminophosphonate, as monitored by ³¹P NMR (14 to 48 h). The solid residue was eliminated by filtration to afford a clear solution of intermediate *N*-chloro α -aminophosphonate and then, poly(4-vinylpyridine) (3.0 g), previously dried at 100 °C overnight, was added. The resulting suspension was stirred under reflux overnight and the reaction was then filtered and concentrated under reduced pressure. The resulting yellow oily crude was purified by crystallization from diethyl ether.

General Procedure for the Synthesis N-Trityl a-Iminophosphonate 14

Following a literature procedure, [33] *N*-bromosuccinimide (178 mg, 1 mmol) was added on a solution of dimethyl ((tritylamino)methyl)phosphonate (457 mg, 1 mmol) in CCl₄ (3 mL). The mixture was stirred in quartz flask under UV light until the disappearance of starting α -aminophosphonate as monitored by ³¹P-NMR (δ H 30.9 to 10.1 ppm). The resulting suspension was filtered under inert atmosphere to afford a clear solution of dimethyl (*E*)-((tritylimino)methyl)phosphonate that can be used without any further workup.

General Procedure for the Ugi Reaction of α -Phosphorated Ketimines 10 and 14

A mixture of α -iminophosphonate 10 or 14 (1 mmol), phenylacetic acid (**11**, 136 mg, 1 mmol) and isocyanide 12 (1.1 mmol) in ichloromethane (3 mL) was stirred at room temperature until disappearance of the starting iminophosphonate 10 as monitored by ³¹P-NMR. The reaction was concentrated under vacuum and the resulting crude residue was purified by crystallization (Dichomethane/Hexanes 1:3), yielding α -aminophosphonates **13**, **15** or **16**. In some cases, a purification by column chromatography was necessary as detailed for each compound.

Dimethyl (2-(cyclohexylamino)-1-((4-methylphenyl)sulfonamido)-2-oxo-1-phenylethyl)

phosphonate (13a). The general procedure was followed, using dimethyl (*E*)-(phenyl(tosylimino)methyl) phosphonate (10a, 367 mg, 1 mmol), phenylacetic acid (11, 136 mg, 1 mmol) and cyclohexyl isocyanide (12a, 136 μ L, 1.1 mmol) to afford 420 mg (85%) of 13a after 1 h as white crystals after crystallization (Dichloromethane/Hexanes 1:3). M.p.: 206–208 °C. ¹H-NMR (400 MHz, CDCl₃) δ 7.25–7.15 (m, 3H, 3 × CH_{Ar}), 7.16 (d, ³J_{HH} = 8.3

Hz, 2H, 2 × CH_{Ar}), 7.05 (d, ³*J*_{HH} = 8.5 Hz, 2H, 2 × CH_{Ar}), 7.00 (d, ³*J*_{HH} = 8.3 Hz, 2H, 2 × CH_{Ar}), 6.76 (d, ³*J*_{HH} = 6.4 Hz, 1H, NHCO), 6.47 (d, ³*J*_{PH} = 8.2 Hz, 1H, NHTs), 3.99 (d, ³*J*_{PH} = 10.7 Hz, 3H, OCH₃), 3.80 (d, ³*J*_{PH} = 10.5 Hz, 3H, OCH₃), 3.77 (m, 1H, CHCy), 2.33 (s, 3H, CH₃Ts), 1.91–1.44 (m, 4H, CH₂Cy), 1.39–0.92 (m, 6H, 3 × CH₂Cy) ppm. ¹³C-NMR {¹H} (101 MHz, CDCl₃) δ 166.1 (C=O), 142.5 (CquatTs), 139.2 (d, ⁴*J*_{PC} = 1.6 Hz, CquatTs), 131.9 (d, ²*J*_{PC} = 1.8 Hz, Cquat Ph), 130.2 (d, ³*J*_{PC} = 8.3 Hz, 2 × CH_{Ar} Ph), 129.1 (2 × CH_{Ar}), 128.7 (CH_{Ar}), 127.9 (2 × CH_{Ar}), 126.5 (2 × CH_{Ar}), 68.5 (d, ¹*J*_{PC} = 157.2 Hz, Cquat-P), 55.8 (d, ²*J*_{PC} = 8.2 Hz, OCH₃), 55.2 (d, ²*J*_{PC} = 7.5 Hz, OCH₃), 49.8 (CHCy), 32.3 (CH₂Cy), 32.1 (CH₂Cy), 25.4 (CH₂Cy), 24.6 (CH₂Cy), 24.5 (CH₂Cy), 21.6 (CH₃Ts) ppm. ³¹P-NMR (121 MHz, CDCl₃) δ 20.5 ppm. FTIR (neat) v_{max}: v = 3426 (N-H st) 3333 (N-H st) 1678 (C=O st) 1256 (P=O st) 1333 (S=O st sym) 1164 (S=O st as) cm⁻¹. HRMS (ESI-TOF) *m*/*z*: [M + H]⁺ calcd for C₂₃H₃₂N₂O₆PS 495.1719, Found 495.1718.

Methyl (2-(dimethoxyphosphoryl)-2-((4-methylphenyl)sulfonamido)-2-phenylacetyl)

glycinate (13b). The general procedure was applied starting from dimethyl (E)-(phenyl(tosylimino)methyl)phosphonate (10a, 367 mg, 1 mmol), phenylacetic acid (11, 136 mg, 1 mmol) and methyl 2-isocyanoacetate (12b, 100 μ L, 1.1 mmol) to afford 378 mg (78%) of 13b after 1 h as a white solid after a chromatography column (Hexanes/AcOEt 1:1), followed by crystallization (Dichloromethane/Hexanes 1:3). M.p.: 130-132 °C. ¹H-NMR (400 MHz, CDCl₃) δ 7.37–7.30 (m, 2H, 2 × CH_{AT}), 7.23–7.16 (m, 3H, 3 × CH_{AT}), 7.15 (d, ³J_{HH} = 5.5 Hz, 1H, NHCO), 7.11–6.95 (m, 4H, 4 × CHAr), 6.64 (d, ³JPH = 6.8 Hz, 1H, NHTs), 4.00 (d, ³*J*_{HH} = 5.5 Hz, 2H, CH₂), 3.91 (d, ³*J*_{PH} = 10.8 Hz, 3H, POCH₃), 3.78 (d, ³*J*_{PH} = 10.6 Hz, 3H, POCH₃), 3.68 (s, 3H, COCH₃), 2.33 (s, 3H, CH₃Ts) ppm. ¹³C-NMR {¹H} (101 MHz, CDCl₃) δ 169.2 (C=O), 167.8 (C=O), 142.7 (CquatTs), 139.0 (CquatTs), 131.5 (CquatPh), 130.2 (d, ³JPC = 7.8 Hz, 2 × CHArPh), 129.1 (2 × CHAr), 128.9 (CHAr), 128.0 (2 × CHAr), 126.7 (2 × CHAr), 69.0 (d, ¹J_{PC} = 155.3 Hz, C_{quat}-P), 55.6 (d, ²J_{PC} = 8.0 Hz, POCH₃), 55.4 (d, ²J_{PC} = 7.5 Hz, POCH₃), 52.5 (COCH₃), 42.2 (CH₂), 21.6 (CH₃Ts) ppm. ³¹P-NMR (121 MHz, CDCl₃) δ 18.9 ppm. FTIR (neat) v_{max} : v = 3437 (N-H st) 3323 (N-H st) 1675 (C=O st) 1266 (P=O st) 1338 (S=O st sym) 1165 (S=O st as) cm⁻¹. HRMS (ESI-TOF) m/z: [M+H]+ calcd for C20H26N2O8PS 485.1147, Found 485.1149.

Dimethyl (2-(benzylamino)-1-((4-methylphenyl)sulfonamido)-2-oxo-1-phenylethyl)

phosphonate (13c). The general procedure was applied starting from dimethyl (E)-(phenyl(tosylimino)methyl) phosphonate (10a, 367 mg, 1 mmol), phenylacetic acid (11, 136 mg, 1 mmol) and (isocyanomethyl) benzene (12c, 134 µL, 1.1 mmol) to afford 402 mg (80%) of **13c** after 1 h as white crystals after a chromatography column (Hexanes/AcOEt 7:3), followed by crystallization (Dichloromethane/Hexanes 1:3). M.p.: 150-152 °C. 1H-NMR (400 MHz, CDCl₃) δ 7.32–7.09 (m, 11H, 11 × CH_{Ar}), 7.08–6.99 (m, 3H, 3 × CH_{Ar}), 6.97 (d, ³*J*_{HH} = 6.3 Hz, 1H, NHCO), 6.74 (d, ³*J*_{PH} = 6.6 Hz, 1H, NHTs), 4.51 (dd, ²*J*_{HH} = 14.9 Hz, ³*J*_{HH} = 6.2 Hz, 1H, C<u>H</u>_ACH_B), 4.35 (dd, ²*J*_{HH} = 14.9 Hz, ³*J*_{HH} = 5.7 Hz, 1H, CH_AC<u>H</u>_B), 3.91 (d, ³J_{PH} = 10.8 Hz, 3H, OCH₃), 3.67 (d, ³J_{PH} = 10.6 Hz, 3H, OCH₃), 2.34 (s, 3H, CH₃Ts) ppm. ¹³C-NMR {¹H} (101 MHz, CDCl₃) & 167.2 (C=O), 142.7 (CquatTs), 139.2 (CquatTs), 137.2 (CquatPh), 132.0 (CquatPh), 130.1 (d, ³JPC = 8.1 Hz, 2 × CHArPh), 129.1 (2 × CHAr), 128.8 (CHAr), 128.7 (2 × CH_{Ar}), 128.1 (2 × CH_{Ar}), 127.8 (2 × CH_{Ar}), 127.7 (CH_{Ar}), 126.6 (2 × CH_{Ar}), 68.8 (d, ¹J_{PC} = 156.0 Hz, Cquat-P), 55.6 (d, ²JPC = 8.0 Hz, OCH₃), 55.1 (d, ²JPC = 7.6 Hz, OCH₃), 44.7 (CH₂), 21.6 (CH₃Ts) ppm. ³¹P-NMR (121 MHz, CDCl₃) δ 19.3 ppm. FTIR (neat) ν_{max}: ν = 3428 (N-H st) 3341 (N-H st) 1675 (C=O st) 1255 (P=O st) 1332 (S=O st sym) 1160 (S=O st as) cm⁻¹. HRMS (ESI-TOF) *m*/*z*: [M + H]⁺ calcd for C₂₄H₂₈N₂O₆PS 503.1406, Found 503.1411.

Diethyl (2-(cyclohexylamino)-1-((4-methylphenyl)sulfonamido)-2-oxo-1-phenylethyl)

phosphonate (13d). The general procedure was applied starting from diethyl (*E*)-(phenyl(tosylimino)methyl) phosphonate (10b, 395 mg, 1 mmol), phenylacetic acid (11, 136 mg, 1 mmol) and cyclohexyl isocyanide (12a, 136 μ L, 1.1 mmol) to afford 434 mg (83%) of 13d after 6 h as white crystals after a chromatography column (Hexanes/AcOEt 8:2),

followed by crystallization (Dichloromethane/Hexanes 1:3). M.p.: 122–124 °C. ¹H NMR (400 MHz, CDCl₃) δ 7.28–7.10 (m, 5H, 5 × CH_{Ar}), 7.05–6.95 (m, 4H, 4 × CH_{Ar}), 6.73 (d, ³J_{HH} = 6.4 Hz, 1H, NHCO), 6.54 (d, ³J_{PH} = 8.1 Hz, 1H, NHTs), 4.47–4.28 (m, 2H, OCH₂), 4.27–4.06 (m, 2H, OCH₂), 3.76 (m, 1H, CHCy), 2.33 (s, 3H, CH₃Ts), 1.91–1.47 (m, 6H, 3 × CH₂Cy), 1.40 (t, ³J_{HH} = 7.0 Hz, 3H, C<u>H</u>₃CH₂), 1.27 (t, ³J_{HH} = 7.0 Hz, 3H, C<u>H</u>₃CH₂) 1.30–0.94 (m, 4H, 2 × CH₂Cy) ppm. ¹³C NMR {¹H} (101 MHz, CDCl₃) δ 166.4 (C=O), 142.4 (CquatTs), 139.3 (CquatTs), 132.1 (CquatPh), 130.4 (d, ³J_{PC} = 7.8 Hz, 2 × CH_ArPh), 129.0 (2 × CH_Ar), 128.6 (CH_Ar), 127.8 (2 × CH_Ar), 126.6 (2 × CH_Ar), 68.6 (d, ¹J_{PC} = 156.2 Hz, Cquat-P), 65.5 (d, ²J_{PC} = 8.3 Hz, OCH₂), 65.0 (d, ²J_{PC} = 7.6 Hz, OCH₂), 49.7 (CHCy), 32.2 (CH₂Cy), 32.2 (CH₂Cy), 25.4 (CH₂Cy), 24.5 (CH₂Cy), 21.5 (CH₃Ts), 16.6 (d, ³J_{PC} = 5.7 Hz, <u>C</u>H₃CH₂), 16.4 (d, ³J_{PC} = 5.8 Hz, <u>C</u>H₃CH₂) ppm. ³¹P-NMR (121 MHz, CDCl₃) δ 17.1 ppm. FTIR (neat) v_{max}: v = 3432 (N-H st) 3340 (N-H st) 1672 (C=O st) 1253 (P=O st) 1338 (S=O st sym) 1165 (S=O st as) cm⁻¹. HRMS (ESI-TOF) *m*/*z*: [M + H]⁺ calcd for C₂₅H₃₆N₂O₆PS 523.2032, Found 523.2034.

Methyl (2-(diethoxyphosphoryl)-2-((4-methylphenyl)sulfonamido)-2-phenylacetyl)glycinate The general procedure was applied starting from diethyl (13e). (E)-(phenyl(tosylimino)methyl) phosphonate (10b, 395 mg, 1 mmol), phenylacetic acid (11, 136 mg, 1 mmol) and methyl 2-isocyanoacetate (12b, 100 µL, 1.1 mmol) to afford 453 mg (88%) of **13e** after 6 h as white crystals after crystallization (Dichloromethane/Hexanes 1:3). M.p.: 147–149 °C. 1H-NMR (400 MHz, CDCl3) & 7.36–7.29 (m, 2H, 2 × CHAr), 7.21–7.11 (m, 4H, 3 × CHAr + NHCO), 7.06–6.92 (m, 4H, 4 × CHAr), 6.61 (d, ³JPH = 6.9 Hz, 1H, NHTs), 4.34–4.19 (m, 2H, OCH₂), 4.18–4.04 (m, 2H, OCH₂), 3.96 (dd, ³J_{HH} = 5.5 Hz, ⁵J_{PH} = 2.7 Hz, 2H, NCH2), 3.65 (s, 3H, OCH3), 2.29 (s, 3H, CH3Ts), 1.30 (t, ³J_{HH} = 6.9 Hz, 3H, CH3CH2), 1.19 (t, ³J_{HH} = 7.0 Hz, 3H, CH₃CH₂) ppm. ¹³C-NMR {¹H} (101 MHz, CDCl₃) δ 169.2 (C=O), 167.9 (C=O), 142.6 (CquatTs), 139.09 (d, ⁴JPC = 1.4 Hz, CquatTs), 131.6 (CquatPh), 130.4 (d, ³JPC = 7.6 Hz, 2 × CH_{Ar}Ph), 129.0 (2 × CH_{Ar}), 128.7 (CH_{Ar}), 127.8 (2 × CH_{Ar}), 126.7 (2 × CH_{Ar}), 69.1 (d, ¹J_{PC} = 153.9 Hz, C_{quat}-P), 65.4 (d, ²J_{PC} = 8.0 Hz, OCH₂), 65.1 (d, ²J_{PC} = 7.5 Hz, OCH₂), 52.4 (OCH₃), 42.2 (NCH₂), 21.5 (CH₃Ts), 16.5 (d, ³J_{PC} = 5.7 Hz, <u>C</u>H₃CH₂), 16.4 (d, ³J_{PC} = 5.6 Hz, <u>CH</u>₃CH₂) ppm. ³¹P-NMR (121 MHz, CDCl₃) δ 16.7 ppm. FTIR (neat) v_{max}: v = 3425 (N-H st) 3331 (N-H st) 1678 (C=O st) 1256 (P=O st) 1332 (S=O st sym) 1165 (S=O st as) cm⁻¹. HRMS (ESI-TOF) *m*/*z*: [M + H]⁺ calcd for C₂₂H₃₀N₂O₈PS 513.1460, Found 513.1462.

Diethyl (2-(benzylamino)-1-((4-methylphenyl)sulfonamido)-2-oxo-1-phenylethyl)

phosphonate (13f). The general procedure was applied starting from diethyl (E)-(phenyl(tosylimino)methyl) phosphonate (10b, 395 mg, 1 mmol), phenylacetic acid (11, 136 mg, 1 mmol) and (isocyanomethyl) benzene (12c, 134 µL, 1.1 mmol) to afford 411 mg (78%) of **13f** after 6 h as white crystals after crystallization (Dichloromethane/Hexanes 1:3). M.p.: 140-142 °C. ¹H-NMR (400 MHz, CDCl₃) δ 7.34-7.14 (m, 10H, 10 × CH_Ar), 7.11-6.97 (m, 5H, 4 × CH_{Ar} + NHCO), 6.69 (d, ³J_{PH} = 5.7 Hz, 1H, NHTs), 4.52 (dd, ²J_{HH} = 14.9, ³J_{HH} = 6.2 Hz, 1H, NCHACHB), 4.44-4.22 (m, 3H, NCHACHB + OCH2), 4.17-3.95 (m, 2H, OCH2), 2.35 (s, 3H, CH₃Ts), 1.35 (t, ³Jнн = 7.0 Hz, 3H, C<u>H</u>₃CH₂), 1.17 (t, ³Jнн = 7.0 Hz, 3H, C<u>H</u>₃CH₂) ppm. ¹³C-NMR {¹H} (101 MHz, CDCl₃) δ 167.5 (C=O), 142.5 (CquatTs), 139.3 (CquatTs), 137.2 (C_{quat}Ph), 132.1 (C_{quat}Ph), 130.2 (d, $^{3}J_{PC}$ = 7.7 Hz, 2 × CH_{Ar}Ph), 129.1 (2 × CH_{Ar}), 128.7 (2 × CHAr), 128.6 (CHAr), 128.0 (2 × CHAr), 127.8 (2 × CHAr), 127.7 (CHAr), 126.6 (2 × CHAr), 68.9 (d, ¹*J*_{PC} = 155.0 Hz, C_{quat}-P), 65.5 (d, ²*J*_{PC} = 8.2 Hz, OCH₂), 65.0 (d, ²*J*_{PC} = 7.5 Hz, OCH₂), 44.7 (NCH₂), 21.6 (CH₃Ts), 16.5 (d, ³*J*_{PC} = 5.7 Hz, <u>C</u>H₃CH₂), 16.3 d, ³*J*_{PC} = 5.7 Hz, <u>C</u>H₃CH₂) ppm. ³¹P-NMR (121 MHz, CDCl₃) δ 16.9 ppm. FTIR (neat) ν_{max}: ν = 3433 (N-H st) 3342 (N-H st) 1679 (C=O st) 1257 (P=O st) 1330 (S=O st sym) 1162 (S=O st as) cm⁻¹. HRMS (ESI-TOF) *m/z*: [M + H]⁺ calcd for C₂₆H₃₂N₂O₆PS 531.1719, Found 531.1728.

Dibenzyl (2-(benzylamino)-1-((4-methylphenyl)sulfonamido)-2-oxo-1-phenylethyl)

phosphonate (**13g**). The general procedure was applied starting from dibenzyl (*E*)-(phenyl(tosylimino)methyl) phosphonate (**10c**, 520 mg, 1 mmol), phenylacetic acid (**11**, 136 mg, 1 mmol) and cyclohexyl isocyanide (**12a**, 136 μL, 1.1 mmol) to afford 583 mg (90%)

of **13g** after 6 h as white crystals after a chromatography column (Hexanes/AcOEt 8:2), followed by crystallization (Ether/Pentane 1:3). M.p.: 80–82 °C. ¹H-NMR (400 MHz, CDCl₃) δ 7.44–7.25 (m, 10H, 10 × CH_{Ar}), 7.24–7.13 (m, 5H, 5 × CH_{Ar}), 7.04 (t, ³*J*_{HH} = 7.7 Hz, 2H, 2 × CH_{Ar}), 6.96 (d, ³*J*_{HH} = 8.1 Hz, 2H, 2 × CH_{Ar}), 6.82 (d, ³*J*_{HH} = 6.6 Hz, 1H, NHCO), 6.44 (d, ³*J*_{PH} = 8.0 Hz, 1H, NHTs), 5.31–5.09 (m, 2H, OCH₂), 5.06–4.91 (m, 2H, OCH₂), 3.77–3.63 (m, 1H, CHCy), 2.33 (s, 3H, CH₃Ts), 1.80–0.81 (m, 10H, 5 × CH₂Cy) ppm. ¹³C-NMR {¹H} (101 MHz, CDCl₃) δ 166.1 (C=O), 142.5 (CquatTs), 139.2 (CquatTs), 135.9 (d, ³*J*_{PC} = 5.2 Hz, CquatBn), 135.7 (d, ³*J*_{PC} = 6.0 Hz, CquatBn), 131.9 (CquatPh), 129.1 (2 × CH_{Ar}), 128.8–128.5 (m, 9 × CH_{Ar}), 128.3 (2 × CH_{Ar}), 128.2 (2 × CH_{Ar}), 127.9 (2 × CH_{Ar}), 126.6 (2 × CH_{Ar}), 70.6 (d, ²*J*_{PC} = 8.0 Hz, OCH₂), 32.0 (CH₂Cy), 25.4 (CH₂Cy), 24.5 (CH₂Cy), 24.5 (CH₂Cy), 21.6 (CH₃Ts) ppm. ³¹P-NMR (121 MHz, CDCl₃) δ (ppm): 17.7 ppm. FTIR (neat) v_{max}: v = 3417 (N-H st) 3324 (N-H st) 1677 (C=O st) 1259 (P=O st) 1336 (S=O st sym) 1162 (S=O st as) cm⁻¹. HRMS (ESI-TOF) *m/z*: [M + H]⁺ calcd for C₃₅H₄₀N₂O₆PS 647.2346, Found 647.2348.

Di-iso-propyl (2-(cyclohexylamino)-1-((4-methylphenyl)sulfonamido)-2-oxo-1-phenylethyl)

phosphonate (13h). The general procedure was applied starting from di-iso-propyl (E)-(phenyl(tosylimino)methyl) phosphonate (10d, 423 mg, 1 mmol), phenylacetic acid (11, 136 mg, 1 mmol) and cyclohexyl isocyanide (12a, 136 μ L, 1.1 mmol) to afford 474 mg (86%) of 13h after 14 h as white crystals after a chromatography column (Hexanes/AcOEt 8:2), followed by crystallization (Dichloromethane/Hexanes 1:3). M.p.: 141-143 °C. 1H-NMR (400 MHz, CDCl₃) 8 7.32–7.27 (m, 2H, 2 × CH_{Ar}), 7.21–7.09 (m, 3H, 3 × CH_{Ar}), 7.05–6.93 (m, 4H, 4 × CH_{Ar}), 6.63 (d, ³*J*_{HH} = 7.3 Hz, 1H, NHCO), 6.58 (d, ³*J*_{PH} = 8.0 Hz, 1H, NHTs), 4.88 (m, 1H, CH₃CH), 4.76 (m, 1H, CH₃CH), 3.77 (m, 1H, CHCy), 2.32 (s, 3H, CH₃Ts), 1.93-1.44 (m, 6H, 3 × CH₂Cy), 1.37 (d, ³J_{HH} = 6.1 Hz, 3H, C<u>H</u>₃CH), 1.36 (d, ³J_{HH} = 6.2 Hz, 3H, C<u>H</u>₃CH), 1.24 (d, ³*J*_{HH} = 6.1 Hz, 3H, C<u>H</u>₃CH), 1.15 (d, ³*J*_{HH} = 6.2 Hz, 3H, C<u>H</u>₃CH), 1.40–0.97 (m, 4H, 2 × CH2Cy) ppm. ¹³C-NMR {¹H} (101 MHz, CDCl₃) δ 166.4 (C=O), 142.3 (C_{quar}Ts), 139.4 (CquatTs), 132.4 (CquatPh), 130.3 (d, ³JPC = 7.7 Hz, 2 × CHAr), 129.0 (2 × CHAr), 128.4 (CHAr), 127.7 (2 × CHAr), 126.7 (2 × CHAr), 73.9 (d, ²J_{PC} = 7.8 Hz, CH₃CH), 73.8 (d, ²J_{PC} = 8.2 Hz, CH₃<u>C</u>H), 68.8 (d, ¹J_{PC} = 156.0 Hz, C_{quat}-P), 49.6 (CHCy), 32.2 (2 × CH₂Cy), 25.5 (CH₂Cy), 24.5 $(d, {}^{3}J_{PC} = 7.2 \text{ Hz}, \underline{C}H_{3}CH), 24.3 (d, {}^{3}J_{PC} = 6.5 \text{ Hz}, \underline{C}H_{3}CH), 24.2 (2 \times CH_{2}Cy), 23.9 (d, {}^{3}J_{PC} = 5.5 \text{ Hz}), 24.2 (2 \times CH_{2}Cy), 23.9 (d, {}^{3}J_{PC} = 5.5 \text{ Hz}), 24.3 (d, {}^{3}J_{PC} = 5.5 \text{ Hz}), 25.3 (d, {}^{3}J_{PC$ Hz, CH3CH), 23.5 (d, ²J_{Pc} = 5.8 Hz, CH3CH), 21.5 (CH3Ts) ppm. ³¹P-NMR (121 MHz, CDCl₃) δ 15.8 ppm. FTIR (neat) vmax: v = 3424 (N-H st) 3345 (N-H st) 1680 (C=O st) 1258 (P=O st) 1335 (S=O st sym) 1165 (S=O st as) cm⁻¹. HRMS (ESI-TOF) m/z: [M + H]⁺ calcd for C27H40N2O6PS 551.2345, Found 551.2348.

Methyl (2-(di-iso-propoxyphosphoryl)-2-((4-methylphenyl)sulfonamido)-2-phenylacetyl)

glycinate (13i). The general procedure was applied starting from diisopropyl (E)-(phenyl(tosylimino)methyl) phosphonate (10d, 423 mg, 1 mmol), phenylacetic acid (11, 136 mg, 1 mmol) and methyl 2-isocyanoacetate (12b, 100 µL, 1.1 mmol) to afford 335 mg (62%) of 13i after 14 h as white crystals after a chromatography column (Hexanes/AcOEt 6:4), followed by crystallization (Dichloromethane/Hexanes 1:3). M.p.: 146–148 °C. ¹H-NMR (400 MHz, CDCl₃) δ 7.44–7.35 (m, 2H, 2 × CH_{Ar}), 7.25–7.14 (m, 4H, 3 × CH_{Ar} + NHCO), 7.08–6.98 (m, 4H, 4 × CHAt), 6.43 (d, ³JPH = 7.8 Hz, 1H, NHTs), 4.82 (hept, ³JHH = 6.0, 1H, С<u>H</u>CH₃), 4.74 (hept, ³J_{HH} = 6.3 Hz, 1H, C<u>H</u>CH₃), 4.03 (d, ³J_{HH} = 5.2 Hz, 2H, CH₂), 3.72 (s, 3H, OCH₃), 2.33 (s, 3H, CH₃Ts), 1.34 (d, ³J_{HH} = 6.0 Hz, 3H, C<u>H</u>₃CH), 1.31 (d, ³J_{HH} = 6.3 Hz, 3H, С<u>Н</u>₃CH), 1.23 (d, ³Jнн = 6.3 Hz, 3H, C<u>H</u>₃CH), 1.11 (d, ³Jнн = 6.0 Hz, 3H, C<u>H</u>₃CH) ppm. ¹³C-NMR {¹H} (101 MHz, CDCl₃) δ 169.3 (C=O), 167.9 (d, ²*J*_{PC} = 1.3 Hz, C=O), 142.6 (C_{quat}Ts), 139.0 (d, ⁴J_{PC} = 1.3 Hz, C_{quat}Ts), 131.8 (d, ²J_{PC} = 1.1 Hz, C_{quat}Ph), 130.3 (d, ³J_{PC} = 7.5 Hz, 2 × CHAr), 129.1 (2 × CHAr), 128.6 (CHAr), 127.7 (2 × CHAr), 126.8 (2 × CHAr), 74.4 (d, ²J_{PC} = 7.9 Hz, CH), 74.1 (d, ²JPC = 8.0 Hz, CH), 69.5 (d, ¹JPC = 152.4 Hz, Cquat-P), 52.5 (OCH₃), 42.2 (CH₂), 24.3 (d, ³*J*_{PC} = 5.0 Hz, <u>C</u>H₃CH), 24.2 (d, ³*J*_{PC} = 4.5 Hz, <u>C</u>H₃CH), 23.8 (d, ³*J*_{PC} = 5.7 Hz, <u>C</u>H₃CH), 23.4 (d, ³*J*_{PC} = 6.0 Hz, <u>C</u>H₃CH), 21.6 (CH₃Ts) ppm. ³¹P-NMR (121 MHz, CDCl₃) δ 15.1 ppm. FTIR (neat) v_{max}: v = 3425 (N-H st) 3334 (N-H st) 1674 (C=O st) 1254 (P=O st) 1330 (S=O st sym) 1163 (S=O st as) cm⁻¹. HRMS (ESI-TOF) m/z: [M + H]⁺ calcd for C₂₄H₃₄N₂O₈PS 541.1773, Found 541.1778.

Di-iso-propyl (2-(benzylamino)-1-((4-methylphenyl)sulfonamido)-2-oxo-1-phenylethyl) phosphonate (13j). The general procedure was applied starting from di-iso-propyl (E)-(phenyl(tosylimino)methyl) phosphonate (10d, 423 mg, 1 mmol), phenylacetic acid (11, 136 mg, 1 mmol) and (isocyanomethyl) benzene (12c, 134 µL, 1.1 mmol) to afford 464 mg (83%) of 13j after 14 h as white crystals after a chromatography column (Hexanes/AcOEt 8:2), followed by crystallization (Dichloromethane/Hexanes 1:3). M.p.: 100-102 °C. ¹H-NMR (400 MHz, CDCl₃) δ 7.39–7.31 (m, 2H, 2 × CH_{Ar}), 7.30–7.13 (m, 8H, 7 × CH_{Ar} + NHCO), 7.06–6.98 (m, 5H, 5 × CHAr), 6.59 (d, ³JPH = 7.4 Hz, 1H, NHTs), 4.85 (hept, ³JHH = 6.2 Hz, 1H, CH), 4.64 (hept, ³*J*_{HH} = 6.1 Hz, 1H, CH), 4.55 (dd, ²*J*_{HH} = 14.9, ³*J*_{HH} = 6.3 Hz, 1H, C<u>H</u>_ACH_B), 4.33 (dd, ²JhH = 14.9, ³JHH = 5.3 Hz, 1H, CHACHB), 2.33 (s, 3H, CH3Ts), 1.33 (d, ³JHH = 6.1 Hz, 3H, CH₃CH), 1.30 (d, ³J_{HH} = 6.2 Hz, 3H, CH₃CH), 1.14 (d, ³J_{HH} = 6.1 Hz, 3H, CH₃CH), 1.06 (d, ³*J*_{HH} = 6.2 Hz, 3H, CH₃CH) ppm. ¹³C-NMR {¹H} (101 MHz, CDCl₃) δ 167.5 (C=O), 142.5 (CquatTs), 139.3 (d, ⁴JPC = 1.3 Hz, CquatTs), 137.2 (CquatPh), 132.4 (CquatPh), 130.2 (d, ³JPC = 7.6 Hz, 2 × CHAr), 129.0 (2 × CHAr), 128.7 (2 × CHAr), 128.5 (CHAr), 127.8 (2 × CHAr), 127.8 (2 × CHAr), 127.7 (CHAr), 126.8 (2 × CHAr), 74.1 (d, ²JPC = 8.0 Hz, 2 × CH), 69.1 (d, ¹JPC = 154.6 Hz, Cquat-P), 44.6 (CH2), 24.3 (d, ²*J*PC = 3.6 Hz, <u>C</u>H3CH), 24.1 (d, ²*J*PC = 3.0 Hz, <u>C</u>H3CH), 23.8 (d, ${}^{2}J_{Pc}$ = 5.8 Hz, C<u>H</u>₃CH), 23.5 (d, ${}^{2}J_{PC}$ = 5.7 Hz, <u>C</u>H₃CH), 21.6 (CH₃Ts) ppm. ${}^{31}P$ -NMR (121 MHz, CDCl₃ δ 15.4 ppm. FTIR (neat) v_{max}: v = 3423 (N-H st) 3336 (N-H st) 1678 (C=O st) 1256 (P=O st) 1331 (S=O st sym) 1162 (S=O st as) cm⁻¹.HRMS (ESI-TOF) *m/z*: [M + H]⁺ calcd for C28H36N2O6PS 559.2032, Found 559.2038.

Dimethyl (2-(cyclohexylamino)-1-((4-methylphenyl)sulfonamido)-1-(4-nitrophenyl)-2-oxoethyl) phosphonate (13k). The general procedure was applied starting from dimethyl (E)-((4-nitrophenyl)(tosylimino)methyl)phosphonate (10e, 412 mg, 1 mmol), phenylacetic acid (11, 136 mg, 1 mmol) and cyclohexyl isocyanide (12a, 136 μ L, 1mmol) to afford 418 mg (78%) of 13k after 1 h as white crystals after a chromatography column (Hexanes/AcOEt 7:3), followed by crystallization (Dichloromethane/Hexanes 1:3). M.p.: 100-102 °C. 1H-NMR (400 MHz, CDCl₃) δ 7.88–7.84 (m, 2H, 2 × CH_{Ar}), 7.52 (d, ³J_{HH} = 8.7 Hz, 2H, 2 × CH_{Ar}), 7.22 (d, ³*J*_{HH} = 8.7 Hz, 2H, 2 × CH_{Ar}), 7.08–7.01 (m, 2H, 2 × CH_{Ar}), 6.79 (d, ³*J*_{HH} = 8.2 Hz, 1H, NHCO), 6.77 (d, ³JPH = 8.1 Hz, 1H, NHTos), 3.96 (d, ³JPH = 10.9 Hz, 3H, OCH₃), 3.76 (d, ³JPH = 10.7 Hz, 3H, OCH₃), 3.76 (m, 1H, CHCy), 2.37 (s, 3H, CH₃Ts), 1.93–1.51 (m, 4H, 2 × CH2Cy), 1.41-0.97 (m, 6H, 3 × CH2Cy) ppm. 13C-NMR [1H] (101 MHz, CDCl3) & 165.0 (C=O), 147.5 (Cquat-NO₂), 143.6 (Cquat Ts), 139.7 (Cquat Ts), 138.8 (CquatAr), 130.9 (d, ³J_{PC} = 7.6 Hz, 2 × CHAr), 129.3 (2 × CHAr), 126.5 (2 × CHAr), 122.8 (2 × CHAr), 67.8 (d, ¹JPC = 153.9 Hz, Cquat-P), 56.0 (d, ²JPC = 8.0 Hz, OCH₃), 55.6 (d, ²JPC = 7.6 Hz, OCH₃), 50.0 (CHCy), 32.3 (CH₂Cy), 32.2 (CH₂Cy), 25.4 (CH₂Cy), 24.6 (CH₂Cy), 24.5 (CH₂Cy), 21.6 (CH₃Ts) ppm. ³¹P-NMR (121 MHz, CDCl3) δ 18.8 ppm. FTIR (neat) vmax: v = 3422 (N-H st) 3346 (N-H st) 1677 (C=O st) 1263 (P=O st) 1348 (S=O st sym) 1165 (S=O st as) cm⁻¹. HRMS (ESI-TOF) m/z: [M + H]⁺ calcd for C₂₃H₃₁N₃O₈PS 540.1569, Found 540.1571.

Dimethyl (1-(4-bromophenyl)-2-(cyclohexylamino)-1-((4-methylphenyl)sulfonamido)-2-oxoethyl)phosphonate (131). The general procedure was applied starting from dimethyl (E)-((4-bromophenyl)(tosylimino)methyl)phosphonate (10f, 446 mg, 1 mmol), phenylacetic acid (11, 136 mg, 1 mmol) and cyclohexyl isocyanide (12a, 136 μ L, 1 mmol) to afford 495 mg (87%) of 13l after 1 h as white crystals after crystallization (Dichloromethane/Hexanes 1:3). M.p.: 150–152 °C. ¹H-NMR (400 MHz, CDCl₃) δ 7.16 (d, ³J_{HH} = 8.3 Hz, 2 × CH_{Ar}), 7.09 (m, seen as s, 4H, 4 × CH_{Ar}), 7.04 (d, ³J_{HH} = 8.3 Hz, 2 × CH_{Ar}), 6.77 (d, ³J_{HH} = 7.4 Hz, 1H, NHCO), 6.60 (d, ³J_{PH} = 8.2 Hz, 1H, NHTs), 3.96 (d, ³J_{PH} = 10.8 Hz, 3H, OCH₃), 3.77 (d, ³J_{PH} = 10.6 Hz, 3H, OCH₃), 3.74 (m, 1H, CHCy), 2.36 (s, 3H, CH₃Ts), 1.91–1.48 (m, 4H, 2 × CH₂Cy), 1.41–0.95 (m, 6H, 3 × CH₂Cy) ppm. ¹³C-NMR {¹H} (101 MHz, CDCl₃) δ 165.7 (C=O), 143.0 (CquarTs), 138.9 (CquarTs), 131.8 (d, ³J_{PC} = 8.1 Hz, 2 × CH_{Ar}), 131.1 (CquatAr), 130.9 (2 × CH_{Ar}), 129.2 (2 × CH_Ar), 126.5 (2 × CH_Ar), 123.4 (C_{quat}-Br), 67.9 (d, ¹*J*_{PC} = 155.9 Hz, C_{quat}-P), 55.9 (d, ²*J*_{PC} = 8.2 Hz, OCH₃), 55.4 (d, ²*J*_{PC} = 7.5 Hz, OCH₃), 49.8 (CHCy), 32.3 (CH₂Cy), 32.2 (CH₂Cy), 25.4 (CH₂Cy), 24.6 (CH₂Cy), 24.5 (CH₂Cy), 21.6 (CH₃Ts) ppm. ³¹P-NMR (121 MHz, CDCl3) δ 19.2 ppm. FTIR (neat) v_{max}: v = 3421 (N-H st) 3320 (N-H st) 1670 (C=O st) 1250 (P=O st) 1343 (S=O st sym) 1165 (S=O st as) cm⁻¹. HRMS (ESI-TOF) *m*/*z*: [M + H]⁺ calcd for C₂₃H₃₁BrN₂O₆PS 573.0824, Found 573.0830.

Dimethyl (1-(4-chlorophenyl)-2-(cyclohexylamino)-1-((4-methylphenyl)sulfonamido)-2-oxoethyl) phosphonate (13m). The general procedure was applied starting from dimethyl (E)-((4-chlorophenyl)(tosylimino)methyl) phosphonate (10g, 402 mg, 1 mmol), phenylacetic acid (11, 136 mg, 1 mmol) and cyclohexyl isocyanide (12a, 136 μ L, 1 mmol) to afford 422 mg (80%) of **13m** after 1 h as white crystals after a chromatography column (Hexanes/AcOEt 7:3), followed by crystallization (Dichloromethane/Hexanes 1:3). M.p.: 165-167 °C. ¹H-NMR (400 MHz, CDCl₃) δ 7.19–7.12 (m, 4H, 4 × CH_{Ar}), 7.04 (d, ³J_{HH} = 8.2 Hz, 2H, 2 × CH_{Ar}), 6.95 (d, ³*J*_{HH} = 8.2 Hz, 2H, 2 × CH_Ar), 6.76 (d, ³*J*_{HH} = 7.2 Hz, 1H, NHCO), 6.58 (d, ³*J*_{PH} = 8.1 Hz, 1H, NHTs), 3.97 (d, ³J_{PH} = 10.8 Hz, 3H, OCH₃), 3.78 (d, ³J_{PH} = 10.6 Hz, 3H, OCH₃), 3.75 (m, 1H, CHCy), 2.36 (s, 3H, CH₃Ts), 1.91–0.95 (m, 10H, 5 × CH₂Cy) ppm. ¹³C-NMR {¹H} (101 MHz, CDCl₃) & 165.7 (C=O), 142.9 (CquatTs), 139.0 (CquatTs), 135.0 (CquatAr), 131.5 (d, ³J_{PC} = 7.7 Hz, 2 × CHAr), 130,6 (Cquat-Cl), 129.1 (2 × CHAr), 128.0 (2 × CHAr), 126.5 (2 × CHAr), 67.8 (d, ¹J_{PC} = 155.9 Hz, Cquat-P), 55.9 (d, ²JPC = 8.2 Hz, OCH₃), 55.4 (d, ²JPC = 7.5 Hz, OCH₃), 49.8 (CHCy), 32.3 (CH₂Cy), 32.2 (CH₂Cy), 25.4 (CH₂Cy), 24.6 (CH₂Cy), 24.5 (CH₂Cy), 21.6 (CH₃Ts) ppm. ³¹P-NMR (121 MHz, CDCl3) δ (ppm): 19.2 ppm. FTIR (neat) v_{max}: v = 3417 (N-H st) 3319 (N-H st) 1670 (C=O st) 1258 (P=O st) 1353 (S=O st sym) 1160 (S=O st as) cm⁻¹. HRMS (ESI-TOF) *m*/*z*: [M + H]⁺ calcd for C₂₃H₃₁ClN₂O₆PS 529.1331, Found 529.1335.

Dimethyl (2-(cyclohexylamino)-1-(2-fluorophenyl)-1-((4-methylphenyl)sulfonamido)-2-oxoethyl) phosphonate (13n). The general procedure was applied starting from dimethyl (E)-((2-fluorophenyl)(tosylimino)methyl) phosphonate (10h, 385 mg, 1 mmol), phenylacetic acid (11, 136 mg, 1 mmol) and cyclohexyl isocyanide (12a, 136 µL, 1 mmol) to afford 370 mg (73%) of 13n after 1 h as white crystals after crystallization (Dichloromethane/Hexanes 1:3). M.p.: 203–205 °C. 1H-NMR (400 MHz, CDCl3) & 7.88 (t, 3JFH = 7.3 Hz, 1H, CHAr), 7.22 (m, 1H, CH_{Ar}), 7.18–7.09 (m, 3H, 3 × CH_{Ar}), 7.03–6.93 (m, 3H, 3 × CH_{Ar}), 6.41 (m, 1H, NHCO), 5.98 (d, ³*J*PH = 8.2 Hz, 1H, NHTs), 4.03 (d, ³*J*PH = 10.7 Hz, 3H, OCH₃), 3.87 (d, ³*J*PH = 10.5 Hz, 3H, OCH₃), 3.75 (m, 1H, CHCy), 2.32 (s, 3H, CH₃Ts), 1.88–1.44 (m, 4H, 2 × CH₂Cy), 1.38–0.78 (m, 6H, 3 × CH₂Cy) ppm. ¹³C-NMR {¹H} (101 MHz, CDCl₃) δ 165.3 (C=O), 160.6 (dd, ¹J_{FC} = 252.7, ³JPC = 13.1 Hz, CF). 142.7 (CquatTs), 138.4 (d, CquatTs), 134.2 (d, ³JFC = 5.2 Hz, CHAr), 131.5 (d, ³*J*_{FC} = 9.1 Hz, CH_{Ar}), 129.0 (2 × CH_{Ar}), 126.6 (2 × CH_{Ar}), 123.9 (d, ⁴*J*_{FC} = 3.4 Hz, CH_{Ar}), 119.9 (dd, ${}^{2}J_{FC} = 10.8$, ${}^{2}J_{PC} = 4.6$ Hz, CquatAr), 115.7 (d, ${}^{2}J_{FC} = 22.5$ Hz, CHAr), 64.6 (d, ${}^{1}J_{PC} = 2.5$ Hz, CHAr), 64.6 (d, {}^{1}J_{PC} = 2.5 Hz, CHAr), 64.6 (d, ${}^{1}J_{PC} = 2.5$ Hz, CHAr), 64.6 (d, {}^{1}J_{PC} = 2.5 H 158.9 Hz, Cquat-P), 56.2 (d, ²JPC = 8.5 Hz, OCH₃), 55.6 (d, ²JPC = 7.7 Hz, OCH₃), 50.0 (CHCy), 32.2 (2 × CH₂Cy), 25.4 (CH₂Cy), 24.7 (CH₂Cy), 24.6 (CH₂Cy), 21.6 (CH₃Ts) ppm. ³¹P-NMR (121 MHz, CDCl3) δ 17.8 ppm. ¹⁹F-NMR (282 MHz, CDCl3) δ –105.5 ppm. FTIR (neat) ν_{max}: v = 3417 (N-H st) 3319 (N-H st) 1672 (C=O st) 1268 (P=O st) 1352 (S=O st sym) 1165 (S=O st as) cm⁻¹. HRMS (ESI-TOF) *m/z*: [M + H]⁺ calcd for C₂₃H₃₁FN₂O₆PS 513.1624, Found 513.1630.

Dimethyl (2-(cyclohexylamino)-1-((4-methylphenyl)sulfonamido)-2-oxo-1-(perfluorophenyl)

ethyl)phosphonate **(130)**. The general procedure was applied starting from dimethyl (*E*)-((perfluorophenyl)(tosylimino)methyl) phosphonate (**10i**, 457 mg, 1 mmol), phenylacetic acid (**11**, 136 mg, 1 mmol) and cyclohexyl isocyanide (**12a**, 136 μ L, 1 mmol) to afford 514 mg (88%) of **13o** after 1 h as white crystals after crystallization (Dichloromethane/Hexanes 1:3). M.p. (Dichloromethane/Hexanes) = 189–191 °C. ¹H-NMR (400 MHz, CDCl₃) δ 7.31 (d, ³J_{HH} = 8.1 Hz, 2H, 2 × CH_{Ar}), 7.11 (d, ³J_{HH} = 8.1 Hz, 2H, 2 × CH_{Ar}), 6.92 (d, ³J_{HH} = 7.3 Hz, 1H, NHCO), 6.40 (br s, 1H, NHTs), 4.01 (d, ³J_{PH} = 10.9 Hz, 3H, OCH₃), 3.82 (d, ³J_{PH} = 10.7 Hz, 3H, OCH₃), 3.79–3.69 (m, 1H, CHCy), 2.36 (s, 3H, CH₃Ts), 1.96–0.94 (m, 10H, 5 × CH₂Cy)

ppm. ¹³C-NMR {¹H} (101 MHz, CDCl₃) δ 164.0 (C=O), 146.4 (m, 2 × CF), 144.0 (C_{quat}Ts), 142.1 (m, 2 × CF), 137.8 (C_{quat}Ts), 137.5 (m, CF), 129.2 (2 × CH_{Ar}), 126.3 (2 × CH_{Ar}), 108.9 (m, C_{quat}Ar), 61.2 (d, ¹*J*_{PC} = 159.7 Hz, C_{quat}-P), 56.4 (d, ²*J*_{PC} = 8.6 Hz, OCH₃), 55.9 (d, ²*J*_{PC} = 8.1 Hz, OCH₃), 50.3 (CHCy), 32.3 (CH₂Cy), 31.9 (CH₂Cy), 25.4 (CH₂Cy), 24.7 (CH₂Cy), 24.6 (CH₂Cy), 21.5 (CH₃Ts) ppm. ³¹P-NMR (121 MHz, CDCl₃) δ 15.9 ppm. ¹⁹F-NMR (282 MHz, CDCl₃) δ -129.4, -151.7, -162.3 ppm. FTIR (neat) v_{max}: v = 3417 (N-H st) 3316 (N-H st) 1677 (C=O st) 1268 (P=O st) 1330 (S=O st sym) 1165 (S=O st as) cm⁻¹. HRMS (ESI-TOF) *m*/*z*: [M + H]⁺ calcd for C₂₃H₂₇F₅N₂O₆PS 585.1249, Found 584.1166.

(2-(cyclohexylamino)-1-((4-methylphenyl)sulfonamido)-2-oxo-1-(4-((trichlorome-Dimethyl thyl)thio)phenyl)ethyl)phosphonate (13p). The general procedure was applied starting from dimethyl (E)-((tosylimino)(4-((trichloromethyl)thio)phenyl)methyl) phosphonate (10j), phenylacetic acid (11, 136 mg, 1 mmol) and cyclohexyl isocyanide (12a, 136 µL, 1 mmol) to afford 580 mg (92%) of **13p** after 14 h as white crystals after a chromatography column (Hexanes/AcOEt 7:3), followed by crystallization (Dichloromethane/Hexanes 1:3). M.p.: 148–150 °C. ¹H-NMR (400 MHz, CDCl₃) δ 7.49 (d, ³J_{HH} = 8.4 Hz, 2H, 2 × CH_Ar), 7.42 (d, ³J_{HH} = 8.4 Hz, 2H, 2 × CH_{Ar}), 7.24 (d, ³J_{HH} = 8.1 Hz, 2H, 2 × CH_{Ar}), 7.06 (d, ³J_{HH} = 8.1 Hz, 2H, 2 × CHAr), 6.75 (d, ³J_{HH} = 6.8 Hz, 1H, NHCO), 6.58 (d, ³J_{PH} = 8.2 Hz, 1H, NHTs), 3.96 (d, ³J_{PH} = 10.8 Hz, 3H, OCH₃), 3.77 (d, ³*J*_{PH} = 10.6 Hz, 3H, OCH₃), 3.71 (m, 1H, CHCy), 2.33 (s, 3H, CH₃Ts), 1.91–1.45 (m, 4H, 2 × CH₂Cy), 1.39–0.94 (m, 6H, 3 × CH₂Cy) ppm. ¹³C-NMR {¹H} (101 MHz, CDCl₃) δ 165.4 (C=O), 143.1 (CquatTs), 139.1 (CquatTs), 136.4 (2 × CHAr), 136.2 (CquatAr), 131.2 (CquatAr) 130.8 (d, ³J_{PC} = 7.9 Hz, 2 × CHAr), 129.3 (2 × CHAr), 126.5 (2 × CHAr), 98.2 (CCl₃), 68.0 (d, ¹J_{PC} = 155.9 Hz, C_{quat}-P), 55.9 (d, ²J_{PC} = 8.1 Hz, OCH₃), 55.4 (d, ²J_{PC} = 7.5 Hz, OCH3), 49.8 (CHCy), 32.2 (CH2Cy), 32.0 (CH2Cy), 25.4 (CH2Cy), 24.5 (CH2Cy), 24.4 (CH2Cy), 21.6 (CH3Ts) ppm. 31P-NMR (121 MHz, CDCl3) & (ppm) 19.0 ppm. FTIR (neat) v_{max}: v = 3412 (N-H st) 3337 (N-H st) 1677 (C=O st) 1265 (P=O st) 1353 (S=O st sym) 1160 (S=O st as) cm⁻¹. HRMS (ESI-TOF) *m/z*: [M + H]⁺ calcd for C₂₄H₃₁Cl₃N₂O₆PS₂ 643.0427, Found 643.0430.

Dimethyl (1-(3-chloro-4-methoxyphenyl)-2-(cyclohexylamino)-1-((4-methylphenyl)-sulfonamido)-2-oxoethyl)-phosphonate (13q). The general procedure was followed, using dimethyl (E)-((3-chloro-4-methoxyphenyl)(tosylimino)-methyl) phosphonate (10k, 431 mg, 1 mmol), phenylacetic acid (11, 136 mg, 1 mmol) and cyclohexyl isocyanide (12a, 136 µL, 1 mmol) to afford 418 mg (75%) of 13q after 14 h as white crystals after crystallization (Dichloromethane/Hexanes 1:3). M.p.: 115-117 °C. 1H-NMR (400 MHz, CDCl3) & 7.45 (m, 1H, CH_{Ar}), 7.34 (d, ³*J*нн = 4.4 Hz, 1H, NHCO), 7.15 (d, ³*J*нн = 8.0 Hz, 2H, 2 × CH_{Ar}), 7.02 (d, ³*J*нн = 8.0 Hz, 2H, 2 × CHAr), 6.78–6.29 (m, 2H, 2 × CHAr), 6.53 (d, ³JPH = 7.5 Hz, 1H, NHTs), 4.04 (d, ³*J*_{PH} = 10.7 Hz, 3H, OCH₃), 3.87 (s, 3H, OCH₃), 3.83 (d, ³*J*_{PH} = 10.4 Hz, 3H, OCH₃), 3.79 (m, 1H, CHCy), 2.34 (s, 3H, CH₃Ts), 1.87–1.02 (m, 10H, 5 × CH₂Cy) ppm. ¹³C-NMR {¹H} (101 MHz, CDCl3) & 165.9 (C=O), 155.2 (Cquat), 143.2 (Cquat Ts), 138.7 (Cquat Ts), 132.0 (d, ³JPC = 10.9 Hz, CH_{At}), 131.0 (d, ³J_{PC} = 6.7 Hz, CH_{At}), 129.2 (2 × CH_{At} Ts), 126.4 (2 × CH_{At} Ts), 124.3 (Cquat), 121.9 (Cquat), 110.2 (CHAr), 67.5 (d, ¹JPC = 157.8 Hz, Cquat-P), 56.3 (OCH3), 56.2 (d, ²JPC = 7.4 Hz, OCH₃), 55.4 (d, ²*J*_{PC} = 7.5 Hz, OCH₃), 49.8 (CHCy), 32.3 (CH₂Cy), 32.2 (CH₂Cy), 25.4 (CH2Cy), 24.6 (CH2Cy), 24.5 (CH2Cy), 21.6 (CH3Ts) ppm. ³¹P-NMR (121 MHz, CDCl₃) δ 19.1 ppm. FTIR (neat) vmax: v = 3434 (N-H st) 3323 (N-H st) 1677 (C=O st) 1258 (P=O st) 1334 (S=O st sym) 1160 (S=O st as) cm⁻¹. HRMS (ESI-TOF) m/z: [M + H]⁺ calcd for C24H33ClN2O7PS 559.1436, Found 559.1437.

Dimethyl (2-(cyclohexylamino)-2-oxo-1-(2-phenyl-N-tosylacetamido)-1-(4-(trifluoromethyl)phenyl)ethyl)phosphonate (**15a**). The general procedure was applied starting from dimethyl (*E*)-((tosylimino)(4-(trifluoromethyl)phenyl)methyl) phosphonate (**10l**, 435 mg, 1 mmol), phenylacetic acid (**11**, 136 mg, 1 mmol) and cyclohexyl isocyanide (**12a**, 136 μL, 1 mmol) to afford 579 mg (85%) of **15a** after 1 h as white crystals after a chromatography column (Hexanes/AcOEt 7:3), followed by crystallization (Dichloromethane/Hexanes 1:3). M.p.: 84–86 °C. ¹H-NMR (400 MHz, CDCl₃) δ 8.20 (d, ³J_{HH} = 8.0 Hz, 2H, 2 × CH_{Ar}), 7.78 (d, ³J_{HH} = 8.3 Hz, 2H, 2 × CH_{Ar}), 7.57 (d, ³J_{HH} = 8.3 Hz, 2H, 2 × CH_{Ar}), 7.36 (d, ³J_{HH} = 8.0 Hz, 2H, 2 × CH_{Ar}), 7.28–7.17 (m, 5H, 5 × CH_{Ar}), 5.95 (br s, 1H, NHCO), 4.20 (d, ²J_{HH} = 17.1 Hz, 1H, C<u>H</u>_ACH_B), 3.98 (d, ²J_{HH} = 17.1 Hz, 1H, CHAC<u>H</u>_B), 3.84 (d, ³J_{PH} = 11.2 Hz, 3H, OCH₃), 3.80–3.68 (m, 1H, CHCy), 3.50 (d, ³J_{PH} = 11.5 Hz, 3H, OCH₃), 2.44 (s, 3H, CH₃Ts), 1.98–0.90 (m, 10H, 6 × CH₂Cy) ppm. ¹³C-NMR {¹H} (101 MHz, CDCl₃) δ 176.6 (C=O), 164.7 (d, ²J_{PC} = 5.2 Hz, C=O), 144.8 (CquatTs), 138.5 Cquat), 138.4 (CquatTs), 133.9 (CquatCF₃), 133.6 (CquatAr), 130.2 (2 × CH_{Ar}), 129.9 (2 × CH_{Ar}), 129.2 (d, ³J_{PC} = 5.3 Hz, 2 × CH_{Ar}), 128.4 (2 × CH_{Ar}), 128.0 (2 × CH_{Ar}), 127.3 (d, ⁴J_{FC} = 3.8 Hz, 2 × CH_{Ar}), 125.1 (CH_Ar), 123.9 (q, ¹J_{FC} = 272.3 Hz, CF₃), 79.4 (d, ¹J_{PC} = 147.5 Hz, Cquat-P), 55.4 (d, ²J_{PC} = 7.3 Hz, OCH₃), 55.1 (d, ²J_{PC} = 7.7 Hz, OCH₃), 49.2 (CHCy), 45.7 (CH₂Bn), 32.4 (CH₂Cy), 31.9 (CH₂Cy), 25.5 (CH₂Cy), 24.6 (CH₂Cy), 24.4 (CH₂Cy), 21.8 (CH₃Ts) ppm. ³¹P-NMR (121 MHz, CDCl₃) δ (ppm): 22.1 ppm. ¹⁹F-NMR (282 MHz, CDCl₃) δ -63.1.ppm. FTIR (neat) v_{max}: v = 3430 (N-H st) 1676 (C=O st) 1248 (P=O st) 1330 (S=O st sym) 1160 (S=O st as) cm⁻¹.HRMS (ESI-TOF) *m*/z: [M + H]⁺ calcd for C₃2H₃₆F₃N₂O₇PS 680.1933, Found 680.1934.

Dimethyl (2-(cyclohexylamino)-1-((4-methylphenyl)sulfonamido)-2-oxo-1-(4-(trifluoromethyl)phenyl)ethyl)phosphonate (13r). Exposure of 15a under air moisture for 48 h yields 13r in quantitative yield as white crystals after crystallization (Dichloromethane/Hexanes 1:3). M.p.: 88–90 °C. 1H-NMR (400 MHz, CDCl3) & 7.36 (d, 3JHH = 7.8 Hz, 2H, 2 × CHAr), 7.22 (d, ³*J*_{HH} = 7.8 Hz, 2H, 2 × CH_{Ar}), 7.11 (d, ³*J*_{HH} = 8.4 Hz, 2H, 2 × CH_{Ar}), 6.98 (d, ³*J*_{HH} = 8.4 Hz, 2H, 2 × CHAr), 6.84 (d, ³J_{HH} = 7.8 Hz, 1H, NHCO), 6.70 (d, ³J_{PH} = 8.1 Hz, 1H, NHTs), 3.99 (d, ³J_{PH} = 10.8 Hz, 3H, OCH₃), 3.80 (m, 1H, CHCy), 3.78 (d, ³*J*PH = 10.6 Hz, 3H, OCH₃), 2.32 (s, 3H, CH3Tos), 1.91-0.94 (m, 10H, 5 × CH2Cy) ppm. ¹³C-NMR {¹H} (101 MHz, CDCl3) & 165.4 (C=O), 143.0 (CquatTs), 138.8 (CquatTs), 135.8 (Cquat), 130.6 (q seen as d, ³JFC = 7.9 Hz, 2 × CHAr), 130.7 (d, ²JPC = 32.8 Hz, CquatCF₃), 129.2 (2 × CH_Ar), 126.3 (2 × CH_Ar), 124.6 (d, ⁴JFC = 3.7 Hz, 2 × CH_{Ar}), 123.7 (q, ¹J_{FC} = 272.5 Hz, CF₃), 68.0 (d, ¹J_{PC} = 155.2 Hz, C_{quat}-P), 55.8 (d, ²J_{PC} = 8.1 Hz, OCH3), 55.5 (d, ²JPC = 7.6 Hz, OCH3), 49.9 (CHCy), 32.2 (CH2Cy), 32.1 (CH2Cy), 25.3 (CH2Cy), 24.6 (CH2Cy), 24.6 (CH2Cy), 21.4 (CH3Tos) ppm. 31P-NMR (121 MHz, CDCl3) & (ppm): 20.0 ppm. ¹⁹F-NMR (282 MHz, CDCl₃) δ -63.5.ppm. FTIR (neat) ν_{max}: ν = 3430 (N-H st) 3332 (N-H st) 1677 (C=O st) 1259 (P=O st) 1326 (S=O st sym) 1165 (S=O st as) cm⁻¹.HRMS (ESI-TOF) *m*/*z*: [M + H]⁺ calcd for C₂₄H₃₀F₃N₂O₆PS 562.1514, Found 562.1519.

Dimethyl (2-(cyclohexylamino)-1-(4-fluorophenyl)-2-oxo-1-(2-phenyl-N-tosylacetamido)

ethyl)phosphonate (15b). The general procedure was followed, using dimethyl (*E*)-(4-fluorophenyl phenyl(tosylimino)methyl) phosphonate (10m, 385 mg, 1 mmol), phenylacetic acid (11, 136 mg, 1 mmol) and cyclohexyl isocyanide (12a, 136 µL, 1 mmol) to afford 536 mg (85%) of **15b** after 14 h as white crystals after column chromatography (Hexanes/Ac-OEt 8:2), followed by crystallization (Dichloromethane/Hexanes 1:3). M.p.: 90-92 °C. ¹H-NMR (400 MHz, CDCl₃) δ ¹H-NMR (400 MHz, CDCl₃) δ 8.26 (d, ³J_{HH} = 7.9 Hz, 2H, 2 × CH_{Ar}), 7.05 (m, 2H, 2 × CH_{Ar}), 7.37 (d, ³J_{HH} = 8.1 Hz, 2H, 2 × CH_{Ar}), 7.28–7.18 (m, 5H, 5 × CH_{Ar}), 7.03 (dd, seen as t, ³*J*_{HH} = 8.5 Hz, ³*J*_{HH} = 8.5 Hz, 2H, 2 × CH_{Ar}), 5.93 (broad s, 1H, NH), 4.17 (d, ²*J*_{HH} = 17.1 Hz, 1H, CH₂), 3.92 (d, ²*J*_{HH} = 17.1 Hz, 1H, CH₂), 3.82 (d, ³*J*_{PH} = 11.2 Hz, 3H, OCH₃), 3.73 (m, 1H, CHCy), 3.50 (d, ³*J*_{PH} = 11.5 Hz, 3H, OCH₃), 2.44 (s, 3H, CH₃Ts), 1.85–0.94 (m, 10H, 5 × CH₂Cy) ppm. ¹³C-NMR {¹H} (101 MHz, CDCl₃) δ 176.4 (C=O), 165.3 (d, ²*J*_{PC} = 4.8 Hz, C=O), 162.4 (d, ¹*J*_{FC} = 248.9 Hz, CAr-F), 144.6 (Cquat), 138.6 (Cquat), 133.8 (Cquat), 131.9 (m, Cquat + 2 × CHAr), 130.2 (2 × CHAr), 129.8 (2 × CHAr), 128.4 (2 × CHAr), 128.0 (2 × CH_{Ar}), 127.2 (CH_{Ar}), 115.2 (d, ²*J*_{FC} = 21.6 Hz, 2 × CH_{Ar}), 78.9 (d, ¹*J*_{PC} = 148.5 Hz, C_{quat}-P), 55.2 (d, ³J_{PC} = 7.2 Hz, CH₃O), 54.9 (d, ³J_{PC} = 7.7 Hz, CH₃O), 48.9 (CH Cy), 45.7 (CH₂ Bn), 32.4 (CH₂ Cy), 31.9 (CH₂ Cy), 25.6 (CH₂ Cy), 24.5 (CH₂ Cy), 24.4 (CH₂ Cy), 21.8 (CH₃ Ts) ppm. ³¹P-NMR (121 MHz, CDCl3) δ 21.8 ppm. ¹⁹F NMR (282 MHz, CDCl₃): δ -113.9 ppm. FTIR (neat) v_{max} : v = 3426 (N-H st) 1677 (C=O st) 1263 (P=O st) 1348 (S=O st sym) 1156 (S=O st as) cm⁻¹. HRMS (ESI-TOF) *m*/*z*: [M + H]⁺ calcd for C₃₁H₃₆FN₂O₇PS 631.2043, Found 631.2040.

Dimethyl (2-(cyclohexylamino)-2-oxo-1-(2-phenylacetamido)ethyl)phosphonate (16). The general procedure was followed, using dimethyl (E)-dimethyl (E)-(phenyl(tritylimino)methyl)phosphonate (14, 455 mg, 1 mmol), phenylacetic acid (11, 136 mg, 1 mmol) and cyclohexyl isocyanide (12a, 136 μ L, 1 mmol) to afford 536 mg (65%) of 16 after 14 h as white crystals after column chromatography (Hexanes/AcOEt 8:2), followed by crystallization (Dichloromethane/Hexanes 1:3). M.p.: 121–122 °C. 1H-NMR (300 MHz, CDCl₃) δ 1H-NMR (400 MHz, CDCl₃) δ 7.43–7.20 (m, 5H, 5 × CHAr), 5.25 (d, ²JPH = 20.6 Hz, 1H, CH-P), 4.91 (br s, 2H, 2 × NH), 3.73 (br s, 3H, OCH₃), 3.70 (br s, 3H, OCH₃), 3.63 (m, 1H, CHCy), 3.58 (s, 2H, CH₂), 1.84–1.65 (m, 4H, 2 × CH₂Cy), 1.36–1.13 (m, 6H, 3 × CH₂Cy) ppm. ¹³C-NMR {¹H} (101 MHz, CD₃OD) & 174.3 (C=O), 172.0 (d, ²J_{PC} = 5.3 Hz, C=O), 135.3 (C_{quat}), 129.0 (2 × CHAr), 128.3 (2 × CHAr), 126.7 (CHAr), 53.5 (d, ³*J*_{Pc} = 6.8 Hz, CH₃O), 53.3 (d, ³*J*_{Pc} = 6.4 Hz, CH₃O), 50.5 (d, ¹J_{PC} = 148.0 Hz, C_{quat}-P), 49.0 (CH Cy), 42.0 (CH₂ Bn), 32.2 (CH₂ Cy), 32.1 (CH₂ Cy), 25.3 (CH₂ Cy), 24.7 (CH₂ Cy), 24.6 (CH₂ Cy) ppm. ³¹P-NMR (121 MHz, CDCl3) δ 21.0 ppm. FTIR (neat) vmax: v = 3436 (N-H st) 3334 (N-H st) 1674 (C=O st) 1265 (P=O st) 1342 (S=O st sym) 1160 (S=O st as) cm⁻¹.HRMS (ESI-TOF) m/z: [M + H]⁺ calcd for C18H27N2O5P, 383.1736, Found 383.1741.

Procedure for the Hydrolysis of Phosphonate Ester 13b

A solution of α -aminophosphonate **13b**, (242 mg, 0.5 mmol) and bromotrimethylsilane (765 mg, 2.5 mmol) was stirred at room temperature in chloroform (3 mL) for 24 h until disappearance of the starting materials as monitored by ³¹P-NMR. Water (3 mL) was then added and the volatiles were distilled off at reduced pressure. The crude residue was crystallized from a mixture Dichloromethane/methanol (95:5) to afford 267 mg (99%) of **23** as a white solid. M.p.: 204–206 °C. ¹H-NMR (400 MHz, D₂O) δ 7.39 (d, ³J_{HH} = 7.3 Hz, 2H, 2 × CH_Ar), 7.25 (d, ³J_{HH} = 8.5 Hz, 2H, 2 × CH_Ar), 7.20–7.14 (m, 2H, 3H, 3 × CH_Ar), 7.12– 7.05 (m, 2H, 2 × CH_Ar), 3.98 (d, ²J_{HH} = 17.9 Hz, 1H, C<u>H</u>_ACH_B), 3.72 (d, ²J_{HH} = 17.9 Hz, 1H, CH_AC<u>H</u>_B), 3.60 (s, 3H, OCH₃), 2.20 (s, 3H, CH₃Ts) ppm. ¹³C-NMR {¹H} (101 MHz, D₂O) δ 171.7 (C=O), 170.7 (C=O), 133.1 (d, ²J_{PC} = 4.3 Hz, C_{quat}), 130.2 (d, ³J_{PC} = 5.8 Hz, 2 × CH_Ar), 129.4 (2 × CH_Ar), 128.1 (CH_Ar), 127.4 (2 × CH_Ar), 126.3 (2 × CH_Ar), 69.9 (d, ¹J_{PC} = 128.5 Hz, C_{quat}-P), 52.8 (OCH₃), 42.0 (CH₂), 20.6 (CH₃Ts) ppm. ³¹P-NMR (121 MHz, D₂O) δ 13.1 ppm. FTIR (neat) v_{max}: v = 3447 (N-H st) 3367 (N-H st) 1674 (C=O st) 1290 (P=O st) 1357 (S=O st sym) 1172 (S=O st as) cm⁻¹. HRMS (ESI-TOF) *m*/*z*: [M + H]⁺ for C₁₈H₂₁N₂O₈PS 457.0834, Found 457.0831.

3.2. Biology

3.2.1. Materials

Reagents and solvents were used as purchased without further purification. All stock solutions of the investigated compounds were prepared by dissolving the powered materials in appropriate amounts of Dimethylsulfoxide (DMSO). The final concentration of DMSO never exceeded 5% (v/v) in reactions. The stock solution was stored at 5 °C until it was used.

3.2.2. Cell Culture

Human epithelial lung carcinoma cells (A549) (ATCC[®] CCL-185[™], ATCC - Manassas, VA, USA) were grown in Kaighn's Modification of Ham's F-12 Medium (ATCC[®] 30-2004[™], ATCC - Manassas, VA, United States) and lung fibroblast cells (MRC5) (ATCC[®] CCL-171[™], ATCC - Manassas, VA, USA) were grown in Eagle's Minimum Essential Medium (EMEM, ATCC[®] 30-2003[™], ATCC - Manassas, VA, USA). Both were supplemented with 10% of fetal bovine serum (FBS) (Sigma-Aldrich, Spain) and with 1% of NORMOCIN solution (Thermo Fisher, Waltham, Massachusetts (MA), United States). Cells were incubated at 37 °C and 5% CO₂ atmosphere, and were split every 3–4 days to maintain monolayer coverage. For cytotoxicity experiments, A549 cells were seeded in 96-well plates at

a density of $2.5-3 \times 10^3$ cells per well and incubated overnight to achieve 70% of confluence at the time of exposition to the cytotoxic compound.

3.2.3. Cytotoxicity Assays

Cells were exposed to different concentrations of the cytotoxic compounds and were incubated for 48 h. Then, 10 μ L of cell counting kit-8 was added into each well for additional two hours incubation at 37 °C. The absorbance of each well was determined by an Automatic Elisa Reader System (Thermo Scientific Multiskan FC Automatic Elisa Reader System, Thermo Scientific, Shangai, China) at 450 nm wavelength.

4. Conclusions

In conclusion, we report an efficient Ugi methodology using ketimines for the preparation of tetrasubstituted α -aminophosphonates holding a variety of substituents. Despite the difficulty often observed for the utilization of ketones or ketimines in Ugi reactions, α -phosphorated ketimines react under mild conditions to give the Ugi adducts after the spontaneous cleavage of the amide moiety. Clear evidences of the Ugi mechanism are provided, using thioacids. Moreover, obtained α -aminophosphonate derivatives **13g**, **13h**, **13p** and **15a** showed in vitro cytotoxicity inhibiting the growth of human tumor cell line A549 (carcinomic human alveolar basal epithelial cell), and a high selectivity toward MRC5 nonmalignant lung fibroblasts. As far as we know this is the first example of much hindered tetrasubstituted α -aminophosphonates showing antiproliferative activity.

Supplementary Materials: ¹H, ¹³C, ¹⁹F and ³¹P-NMR copies of compounds 13, 15, 16, 23.

Author Contributions: Conceptualization, A.L.-F., X.d.C., E.M.d.M., F.P. and J.V.; methodology, A.L.-F. and X.d.C.; software, A.L.-F. and X.d.C.; validation, E.M.d.M. and J.V.; formal analysis, A.L.-F. and X.d.C.; investigation, A.L.-F. and X.d.C.; resources, E.M.d.M., F.P. and J.V.; data curation, A.L.-F. and X.d.C.; writing—original draft preparation, J.V.; writing—review and editing, A.L.-F., X.d.C., E.M.d.M., F.P. and J.V.; visualization, E.M.d.M., F.P. and J.V.; supervision, E.M.d.M. and J.V.; project administration, E.M.d.M. and J.V.; funding acquisition, E.M.d.M., F.P. and J.V. All authors have read and agreed to the published version of the manuscript.

Funding: Financial support by Ministerio de Economía, Industria y Competividad (MINECO, CTQ-2015-67871R) and Gobierno Vasco (GV, IT 992-16) is gratefully acknowledged. X.d.C. and A.L.-F. thank the Basque Country Government for a predoctoral grant.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: The data presented in this study are available in the supplementary materials file or on request from the corresponding author (¹H, ¹³C, ¹⁹F and ³¹P-NMR and HRMS spectra and cytotoxicity essays).

Acknowledgments: The authors thank for technical and human support provided by SGIker (UPV/EHU/ERDF, EU).

Conflicts of Interest: The authors declare no conflict of interest.

Sample Availability: Samples of the compounds are not available.

References

- 1. Knapp, J.M.; Kurth, M.J.; Shaw, J.T.; Younai, A. *Diversity-Oriented Synthesis*; Trabocchi, A., Ed.; Willey: New York, NY, USA, 2013; pp. 29–57.
- 2. Galloway, W.; Isidro-Llobet, A.; Spring, D. Diversity-oriented synthesis as a tool for the discovery of novel biologically active small molecules. *Nat. Commun.* **2010**, *1*, 80–93.
- 3. Schreiber, S.L. Target-oriented and diversity-oriented organic synthesis in drug discovery. Science 2000, 287, 1964–1969.
- 4. de Moliner, F.; Kielland, N.; Lavilla, R.; Vendrell, M. Modern Synthetic Avenues for the Preparation of Functional Fluorophores. *Angew. Chem. Int. Ed.* **2017**, *56*, 3758–3769.
- Hall, D.G.; Rybak, T.; Verdelet, T. Multicomponent Hetero-[4 + 2] Cycloaddition/Allylboration Reaction: From Natural Product Synthesis to Drug Discovery Acc. Chem. Res. 2016, 49, 2489.

- 6. Zhu, J.; Wang, Q.; Wang, M.-X. (Eds.) Multicomponent Reactions in Organic Synthesis; Wiley-VCH: Weinheim, Germany, 2015.
- 7. Müller, T.J.J. Science of Synthesis, Multicomponent Reactions; Thieme: Stutgart, Germany, 2014; Volume 1 and 2.
- 8. Ugi, I.; Meyr, R.; Fetzer, U.; Steinbrükner, C. Versuche mit Isonitrilen. Angew. Chem. 1959, 71, 386.
- 9. Dömling A, Ugi, L. Multicomponent Reactions with Isocyanides. Angew. Chem. Int. Ed. Engl. 2000, 39, 3168–3210.
- 10. Dömling, A. Recent developments in isocyanide based multicomponent reactions in applied chemistry. *Chem. Rev.* **2006**, *106*, 17–89.
- 11. Dömling, A.; Wang, W.; Wang, K. Chemistry and Biology Of Multicomponent Reactions. Chem. Rev. 2012, 112, 3083–3135.
- 12. Fouad, M.A.; Abdel-Hamid, H.; Ayoup, M.S. Two decades of recent advances of Ugi reactions: Synthetic and pharmaceutical applications. *RSC Adv.* **2020**, *10*, 42644–42681.
- 13. Touré, B.B.; Hall, D.G. Natural Product Synthesis Using Multicomponent Reaction Strategies. Chem. Rev. 2009, 109, 4439–4486.
- 14. Kafarski, P.; Lejczak, B. Aminophosphonic Acids of Potential Medical Importance. *Curr. Med. Chem. Anti-Cancer Agents* **2001**, *1*, 301–312.
- 15. Hiratake J.; Oda, J. Aminophosphonic and Aminoboronic Acids as Key Elements of a Transition State Analogue Inhibitor of Enzymes. *Biosci. Biotechnol. Biochem.* **1997**, *61*, 211–218.
- 16. Kafarski, P.; Lejczak, B. Biological Activity of Aminophosphonic Acids B. Phosphorus. Sulfur. Silicon 1991, 63, 193–215.
- 17. Berlicki, L.; Kafarski, P. Computer-Aided Analysis and Design of Phosphonic and Phosphinic Enzyme Inhibitors as Potential Drugs and Agrochemicals. *Curr. Org. Chem.* **2005**, *9*, 1829–1850.
- 18. Van der Jeught, K.; Stevens. C. V. Direct Phosphonylation of Aromatic Azaheterocycles. Chem. Rev. 2009, 109, 2672–2702.
- 19. Barrett, G.; Elmore, D. Amino Acids and Peptides; Cambridge University Press: Cambridge, UK, 1998.
- 20. Aminophosphonic and Aminophosphinic Acids. Chemistry and Biological Activity; Kukhar, V.P., Hudson, H.R., Eds.; Wiley: Chichester, UK, 2000.
- 21. Ghashghaei, O.; Manna, C. A.; Vicente-García, E.; Revés, M.; Lavilla, R. Studies on the interaction of isocyanides with imines: Reaction scope and mechanistic variations *Beilstein J. Org. Chem.* **2014**, *10*, 12–17.
- Foley, C.; Shaw, A.; Hulme, C. .Aza-Riley Oxidation of Ugi-Azide and Ugi-3CR Products toward Vicinal Tricarbonyl Amides: Two-Step MCR-Oxidation Methodology Accessing Functionalized α,β-Diketoamides and α,β-Diketotetrazoles. Org. Lett. 2018, 20, 1275–1278.
- 23. Quaternary Stereocentres: Challenges and Solutions for Organic Synthesis; Christoffers, J., Baro, A., Eds.; Wiley-VCH: Weinhein, Germany, 2006.
- Yamada, T.; Yanagi, T.; Omote, Y.; Miyazawa, T.; Kuwata, S.; Sugiura, M.; Matsumoto, K. Four-component condensation (Ugi reaction) at high pressure: Novel synthesis of peptides containing very bulky α,α-disubstituted glycines. *J. Chem. Soc. Chem. Commun.* 1990, 1640–1641, doi:10.1039/C39900001640.
- Costa, S.P.G.; Maia, H.L.S.; Pereira-Lima, S.M.M.A. An improved approach for the synthesis of α,α-dialkyl glycine derivatives by the Ugi–Passerini reaction. *Org. Biomol. Chem.* 2003, *1*, 1475–1479.
- Pinto, F.C.S.C.; Pereira-Lima, S.M.M.A.; Ventura, C.; Albuquerque, L.; Concalves-Maia, R.; Maia, H.L.S. Synthesis and kinetic investigation of the selective acidolysis of *para*-substituted *N*-benzyl- or *N*-phenyl-*N*-phenylacetyl-α,α-dialkylglycine cyclohexylamides *Tetrahedron* 2006, 62, 8184–8198.
- Maestro, A.; Del Corte, X.; Martínez de Marigorta, E.; Palacios, F.; Vicario, J Enantioselective synthesis of functionalized αaminophosphonic acid derivatives. *Phosphorus. Sulfur. Silicon* 2019, 194, 287–291.
- Vicario, J.; Ezpeleta, J.M.; Palacios, F. Asymmetric Cyanation of α-Ketiminophosphonates Catalyzed by Cinchona Alkaloids. Enantioselective Synthesis of Tetrasubstituted α-Aminophosphonic Acid Derivatives From Trisubstituted α-Aminophosphonates. *Adv. Synth. Catal.* 2012, 354, 2641–2647.
- Vicario, J.; Ortiz, P.; Palacios, F. Synthesis of Tetrasubstituted α-Aminophosphonic Acid Derivatives from Trisubstituted α-Aminophosphonates. *Eur. J. Org. Chem.* 2013, 7095–7100, doi:10.1002/ejoc.201300950.
- Vicario, J.; Ortiz, P.; Ezpeleta, J.M.; Palacios, F. Asymmetric Synthesis of Functionalized Tetrasubstituted α-Aminophosphonates through Enantioselective Aza-Henry Reaction of Phosphorylated Ketimines. J. Org. Chem. 2015, 80, 156–164.
- 31. Maestro, A.; Martínez de Marigorta, E.; Palacios, F.; Vicario, J. Enantioselective Aza-Reformatsky Reaction with Ketimines. *Org. Lett.* **2019**, *21*, 9473–9477.
- 32. Ling, T.; Rivas, F. All-carbon quaternary centers in natural products and medicinal chemistry: Recent advances. *Tetrahedron* **2016**, *72*, 6729–6777.
- Maestro, A.; Martín-Encinas, E.; Alonso, C.; Rubiales, G.; Martínez de Marigorta, E.; Vicario, J.; Palacios, F. Synthesis of novel antiproliferative hybrid bis-(3-indolyl)methane phosphonate derivatives. *Eur. J. Med. Chem.* 2018, 158, 874–883.
- Recio, R.; Vengut-Climent, E.; Mouillac, B.; Orcel, H.; López-Lázaro, M.; Calderón-Montaño, J.M.; Alvarez, E.; Khiar, N.; Fernández. I.; Design, synthesis and biological studies of a library of NK1-Receptor Ligands Based on a 5-arylthiosubstituted 2-amino-4,6-diaryl-3-cyano-4*H*-pyran core: Switch from antagonist to agonist effect by chemical modification. *Eur. J. Med. Chem.* 2017, 138, 644.
- 35. Müller, K.; Faeh, C.; Diederich, F. Fluorine in pharmaceuticals: Looking beyond intuition. Science 2007, 317, 1881.
- 36. Shah, P.; Westwell, A.D. The role of fluorine in medicinal chemistry. J. Enzyme Inhib. Med. Chem. 2007, 22, 527.
- 37. Bégué, J.P.; Bonnet-Delpon, D. Bioorganic and Medicinal Chemistry of Fluorine; Wiley: Hoboken, NJ, USA, 2007; pp. 1–365.